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Abstract 
The adipose triglyceride lipase (ATGL) is the main enzyme to catalyze the first and rate-
limiting step in stimulated lipolysis in white adipose tissue. This 3-step-process is re-
quired to release free fatty acids from cytosolic triglyceride stores, called lipid droplets. 
The fatty acids are transported to various parts of the body, mainly muscles and liver. 
Given their high energy density, fatty acids are the most important substrates for ATP 
production but they are also needed as second messengers, regulators of gene expres-
sion and components of biological membranes. 
Mice deficient for a functional ATGL display a severe phenotype of massive TG accumu-
lation throughout the body which causes multiple metabolic disorders. The first mice die 
from cardiac insufficiency at the age of 12 weeks. In the human ATGL gene several au-
tosomal recessive mutations have been described that cause neutral lipid storage dis-
ease with myopathy (NLSDM) which is characterized by a similar phenotype as in Atgl-/- 
mice. 
Lipid profiling analysis in Atgl-/- mice revealed a reduction in C22:6n-3 (DHA)-containing 
phospholipids and triglycerides in the cardiac muscle whereas C18:0/C18:1/C18:2-
containing lipids were increased. Docosahexaenoic acid (DHA) is a ω3-polyunsaturated 
fatty acid (PUFA) which is concentrated mainly in brain and retina and is needed for 
neural and retinal development. DHA itself and its derivatives (docosatrienes, resolvins) 
have many anti-inflammatory functions. DHA either has to be taken up with the diet or is 
synthesized from its precursor α-linolenic acid (C18:3n-3) which is an essential fatty acid 
that is enriched in vegetable oils. The liver is the main organ for DHA biosynthesis; the 
brain can also synthesize minor amounts whereas the quantities produced in the heart 
are marginal. 
The aim of this study was to find the missing link between ATGL deficiency and reduced 
levels of DHA-containing lipids. By real-time PCR measurements, ATGL was identified 
as regulator of DHA (or PUFA) synthesis. In the liver of mice, the expression of selected 
enzymes involved in DHA-biosynthesis was induced by fasting but failed to be upregu-
lated when ATGL was missing. Expression in the heart was independent of the nutrition-
al status as relative expression levels were downregulated in both, fed and fasted mice, 
when ATGL was missing. Real-time PCR as well as Northern blotting analysis showed 
that (most of the) selected enzymes are PPARα target genes, in liver as well as in the 
heart. Thus, ATGL deficiency could have inhibited PPARα-activated gene expression in 
ATGL-knockout mice. Most probably, ATGL provides ligands for PPARα-activation. This 
mechanism seems to be regulated by the diet in the liver but not in the heart - provided 
that changed expression levels in the heart of (fed) Atgl-/- mice are linked at all to 
PPARα. HPLC-MS/MS revealed that DHA levels were not increased in cardiac muscle of 
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Atgl-/- mice by induction of PPARα-activity upon administration of the synthetic PPARα 
agonist WY14,643. Therefore, the regulation of PPARα-induced gene expression of 
DHA-synthesizing enzymes is definitely not the only function of ATGL in this pathway. 
Most likely, ATGL is further needed to release the precursor for DHA-biosynthesis from 
triglycerides and/or phospholipids but this remains to be verified. 
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Zusammenfassung 
Die Fettgewebstriglyzeridlipase (adipose (tissue) triglyceride lipase; ATGL) ist das 
primäre Enzym für die Katalyse des ersten und geschwindigkeitsbestimmenden Schrittes 
der stimulierten Lipolyse im weißen Fettgewebe. Dieser 3-stufige Prozess ist notwendig, 
um freie Fettsäuren aus den zytosolischen Triglyzeridspeichern, den Lipidtröpfchen, 
freizusetzen. Die Fettsäuren werden in verschiedene Teile des Körpers transportiert, vor 
allem zum Muskelgewebe und zur Leber. Sie sind die wichtigsten, da energiereichsten 
Substrate für die Produktion von ATP, werden aber auch als sekundäre Botenstoffe, als 
Regulatoren der Genexpression und als Komponenten von biologischen Membranen 
benötigt.  
Mäuse, denen eine funktionelle ATGL fehlt, zeigen einen schwerwiegenden Phänotyp, 
der mit massiver Triglyzeridakkumulation im gesamten Körper und zahlreichen damit 
verbundenen Stoffwechselstörungen einhergeht. Die ersten Mäuse sterben infolge einer 
Herzschwäche im Alter von 12 Wochen. Im menschlichen Gen für ATGL wurden 
mehrere autosomal rezessive Mutationen beschrieben, die eine mit Myopathie 
assoziierte Neutrallipidspeicherkrankheit (NLSDM) verursachen, welche sich durch einen 
ähnlichen Phänotyp wie in ATGL-knockout-Mäusen beschrieben auszeichnet. 
Die Analyse des Lipidprofils in Atgl-/--Mäusen ergab einen verminderten Anteil an DHA 
(C22:6n-3)-enthaltenden Phospolipiden und Triglyzeriden im Herzmuskel, wohingegen 
Lipide, die C18:0/C18:1/C18:2 enthalten, erhöht waren. Die Docosahexaensäure 
(docosahexaenoic acid/DHA) ist eine mehrfach ungesättigte ω3-Fettsäure, die 
hauptsächlich im Gehirn und der Netzhaut angereichert ist, für deren Entwicklung sie 
unabdingbar ist. DHA und ihre Stoffwechselprodukte haben vielerlei 
entzündungshemmende Wirkmechanismen. DHA muss entweder mit der Nahrung 
zugeführt werden oder wird aus ihrem Vorläufer, der α-Linolensäure (C18:3n-3), 
synthetisiert. Die α-Linolensäure ist eine essentielle Fettsäure, die hauptsächlich in 
pflanzlichen Ölen angereichert ist. Die Leber ist das Hauptorgan für die Synthese von 
DHA, auch das Hirn kann kleinere Mengen produzieren, während im Herzen nur ein 
verschwindend geringer Anteil synthetisiert wird. 
Das Ziel dieser Arbeit war, die fehlende Verbindung zwischen mangelnder ATGL und 
verringerten Mengen an DHA-enthaltenden Lipiden herauszufinden. Mittels real-time 
PCR konnte die ATGL als Regulator der DHA (oder PUFA)-Synthese ermittelt werden. In 
der Mausleber wurde die Expression von ausgewählten Enzymen des DHA-
Syntheseweges durch Fasten induziert, während dieser Effekt nicht auftrat, wenn die 
ATGL fehlte. Die Expression im Herz war unabhängig vom Fütterungszustand, denn die 
relativen mRNA-Mengen waren sowohl in gefütterten als auch gefasteten ATGL-
knockout-Mäusen reduziert. Von den (meisten der) untersuchten Enzyme konnte mittels 
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real-time PCR und Northern blot gezeigt werden, dass sie sowohl in der Leber auch als 
im Herz PPARα-Zielgene sind. Das Fehlen der ATGL könnte also die PPARα-vermittelte 
Genexpression verhindert haben. Wahrscheinlich stellt die ATGL die Liganden für die 
Aktivierung von PPARα während des Fastens bereit. Dieser Mechanismus wird in der 
Leber über die Nahrung reguliert, aber nicht im Herz – falls die Expressionsänderung im 
Herz von (gefütterten) ATGL-knockout-Mäusen überhaupt mit PPARα in Verbindung 
steht. Die HPLC-MS/MS zeigte, dass der Anteil an DHA im Herzmuskel von Atgl-/--
Mäusen nach Aktivierung von PPARα durch den synthetischen Agonisten WY14,643 
nicht wieder gestiegen ist. Daher ist die Regulation von PPARα-induzierter 
Genexpression in jedem Fall nicht die einzige Funktion der ATGL in diesem 
Stoffwechselweg. Am wahrscheinlichsten ist, dass die ATGL dazu benötigt wird, den 
Vorläufer für die DHA-Synthese aus Triglyzeriden und Phospholipiden freizusetzen; das 
muss aber erst bestätigt werden..  
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1. Introduction 
 
1.1. Lipid Metabolism in mammals 
Fatty acids (FA) are the main building blocks of all lipid classes throughout the body and 
the most important substrates for energy production by β-oxidation inside mitochondria 
(1). These carboxylic acids are characterized by a hydrophilic head and a hydrophobic 
tail. The tail is a hydrocarbon chain of varying length - naturally occurring chains range 
from four to 28 carbon atoms (1, 2, 3). The number of double bonds incorporated in the 
tail is used to classify fatty acids as saturated (no double bond), monounsaturated (one 
double bond) or polyunsaturated (2 or more double bonds) (Fig.1.1.1) (1). Fatty acids 
can also be classified according to their chain length as short chain (4 carbon atoms), 
medium chain (6-12 carbon atoms), long chain (>12-20 carbon atoms) and very long 
chain (22 – over 30 carbon atoms) fatty acids (4). 
        
FIGURE 1.1.1. Structure of saturated and unsaturated fatty acids (left) and triglycerides (right). Left: A 
saturated fatty acid with a chain of 10 carbon atoms. Middle: A monounsaturated C10 fatty acid. Right: A 
triglyceride (TG), also called triacylglycerol (TAG), formed by esterification of three FA on a glycerol back-
bone (Image source: (5)).  
 
Fatty acids in food, taken up by ingestion of animal or vegetable fat and oil, mostly form 
triglycerides (TG), where three FA at a time are esterified onto a glycerol backbone (6). 
These triglycerides account for about 90% to 95% of daily human energy supply pro-
vided by dietary fat (7). Some triglycerides are already broken down into diglycerides and 
free fatty acids (FFA) in the stomach by lingual and gastric lipases. They are further 
processed into monoglycerides and fatty acids by pancreatic lipases in the duodenum (8, 
9). In the small intestine monoglycerides, free fatty acids, glycerol, and cholesterol are 
emulsified by bile salts and form micelles which are absorbed by intestinal enterocytes 
(10). Inside these epithelial cells, fatty acids are reesterified into triglycerides by monoa-
cylglycerol acyltransferase (MGAT) and diacylglycerol acyltransferase (DGAT) (11, 12) 
and packaged into lipoprotein particles called chylomicrons together with cholesterol, 
phospholipids and apolipoprotein B-48 (ApoB-48). These particles first enter the lymph 
system and are subsequently released into the blood system and transported to various 
organs (13, 14). As a result of lipoprotein lipase activity fatty acids are again released 
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from triglycerides (and thereby from lipoprotein particles) and then taken up via passive 
or facilitated diffusion by cells of extrahepatic organs for energy supply or storage (15). 
The remainder of these particles (chylomicron remnants) is taken up by liver cells and 
metabolized (16). 
 
FIGURE 1.1.2. Digestion and absorption of dietary TAG. Left: The digestion of dietary TAG already starts 
in the stomach where lingual and gastric lipases cleave part of the TAG into DAG, FA and glycerol. DAG and 
remaining TAG are further processed to MAG, glycerol and FA in the small intestine by pancreatic lipase 
(image source: (17)). Right: The cleavage products form micelles through the emulsifying action of bile salts 
and are absorbed by enterocytes. Inside these epithelial cells, fatty acids are reesterified to TAG by the 
action of MGAT and DGAT and together with cholesterol esters and apoB are packaged into chylomicrons 
and released into the lymph system (image source: (18)). CL, cholesterol; BS, bile salt; FA, fatty acid(s); PL, 
phospholipid; MAG, monoacylglycerol; MGAT, monoacylglycerol acyltransferase; DGAT, diacylglycerol acyl-
transferase; CE, cholesterol ester; ApoB, apolipoprotein B; CM, chylomicron. 
 
If nutritional energy supply exceeds the energy requirements, fatty acids are stored in 
form of TG in small and very dynamic cytosolic organelles called lipid droplets (19, 20). 
Lipid droplets exist in every organ and cell of the body (21). Nevertheless, mammalians 
store fat mainly in the white adipose tissue (WAT) (21). The storage of excess fatty acids 
not only serves as energy source but also prevents toxic concentration of free fatty acids 
in the cell which would severely disrupt cell function, for instance by destroying biological 
membranes (22).  
During times of increased energy demand like fasting or exercising stored fatty acids 
need to be released from these cytosolic triglyceride stores by a process called lipolysis 
(23). Lipolysis is a three-step process which is catalyzed by three different enzymes. The 
first and rate-limiting step, which is catalyzed by the adipose triglyceride lipase (ATGL), 
is the hydrolysis of triglycerides into diglycerides (DG) and free fatty acids (FFA). Next, 
the hormone sensitive lipase (HSL) cleaves diglycerides into monoglycerides (MG) and 
free fatty acids. In the last step monoglycerides are hydrolyzed into glycerol and free 
fatty acids by the monoglyceride lipase (MGL) (21, 24). These free fatty acids enter the 
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blood stream where they bind to serum albumin and are transported to various organs 
and tissues, mainly muscle tissue and liver. They are used for energy/ATP production, 
for membrane biogenesis, for regulation of gene expression (e.g. as ligands for nuclear 
receptors) and for ketogenesis/gluconeogenesis in the liver (20, 21, 22). Furthermore 
FFA but also other lipolysis intermediates (e.g. DG) serve as second messengers in sig-
nal transduction pathways (21, 25). Energy is also consumed by brown adipose tissue 
(BAT) which needs fatty acids for thermogenesis/heat production inside mitochondria. 
Humans lose this specialized adipose tissue during childhood whereas rodents and hi-
bernating animals keep it throughout life (26, 27).  
 
1.2. ATGL 
The adipose triglyceride lipase (ATGL) was discovered only recently, in 2004, by three 
different research groups (28, 29, 30). Until then, the hormone sensitive lipase (HSL) 
was thought to catalyze both the first and the second step of lipolysis. ATGL cleaves 
triglycerides with 10-fold higher substrate specificity than diglycerides (21). It is highly 
expressed in white and brown adipose tissue. At lower levels it is found in cardiac mus-
cle, skeletal muscle and testis (28). Transcription of ATGL is regulated by hormones, 
cytokines and fasting/refeeding which confirms its critical role in lipolysis (28, 31).  
ATGL is a member of the patatin-like phospholipase domain containing family of proteins 
(PNPLA1-5) (21). It is also called PNPLA2 (official designation), desnutrin (29), or cal-
cium-independent phospholipase A2ζ (iPL-A2ζ) (30, 31). The murine gene spans nine 
exons on chromosome 7 with a size of 4.9 kb. The protein is built up by 486 aa with a 
calculated molecular mass of 54 kDa (32). The human gene (504 aa) comprises ten ex-
ons on chromosome 11p15.5 with sequence similarity of 84% to its mouse homologue 
and, regarding the patatin domain, even of more than 95% (21, 28, 33). The N-terminal 
patatin domain is structurally characterized by a three-layered α/β/α sandwich architec-
ture and contains the lipase consensus sequence motif GXSXG with the nucleophilic 
serine at position 47 (Ser47) (34, 35). The enzymatic activity of this phospholipase do-
main untypically is given by a catalytic dyad instead of a triad (36). In addition to the ac-
tive serine, the catalytic dyad is made up by an asparagine (Asp166) outside the central 
β-sheet (37). A hydrophobic stretch in the C-terminal region, which is composed mainly 
of α-helices and loop regions, is needed for the localization of ATGL to the lipid droplet 
but compromises the enzymatic activity (38). It also includes two phosphorylation sites 
(Ser404;Ser428 in human ATGL) but it remains to be elucidated whether the phosphoryla-
tion status influences the protein’s activity (21, 38). 
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FIGURE 1.2.1. Predicted structure of the human ATGL protein (39). Protein map of human ATGL dis-
playing the N-terminal patatin domain that contains the lipase consensus sequence motif GXSXG with the 
active serine at position 47. The α/β-hydrolase fold (represented by the blue box underneath) is also N-
terminally located inside the ATGL protein whereas the C-terminus harbors a hydrophobic region. aa, amino 
acid(s); GXSXG: G, glycine; S. serine; X, any aa (image adapted from: (39)). 
 
1.3. Regulation of lipolysis 
The protein encoded by comparative gene identification-58, CGI-58, was shown to bind 
to murine ATGL thereby increasing its activity by up to 20-fold (40). The same effect, 
although much weaker, was observed for human ATGL with a 5-fold induction of the 
enzyme’s activity through binding of CGI-58 (21, 40). 
CGI-58 belongs to the esterase/thioesterase/lipase family of proteins which is structurally 
characterized by α/β-hydrolase folds (41). In CGI-58 the active serine within the lipase 
motif GXSXG is replaced by an asparagine (42) therefore it has no lipolytic activity. At 
basal level, CGI-58 binds to lipid droplets within adipocytes by interacting with perilipin A 
and therefore can no longer bind to and activate ATGL (43). Perilipin A is a member of 
the PAT or perilipin family of proteins that are lipid droplet coat proteins (41). Activa-
tion/regulation of lipolysis includes a series of phosphorylation/dephosphorylation events 
(44). During fasting, for instance, glucagon and/or catecholamines (e.g. adrenaline) are 
secreted. They bind to their respective (glucagon or β-adrenergic) receptors thereby sti-
mulating G-proteins which in turn activate the adenylyl cyclase (45). The induction of this 
enzyme results in increased cyclic AMP (cAMP) levels. cAMP molecules bind to the reg-
ulatory subunits of the cAMP-dependant protein kinase (PKA) and free its catalytic sub-
units (6). PKA phosphorylates perilipin A which releases CGI-58. CGI-58 can now bind to 
and activate ATGL, however the exact mechanism of activation is not yet known. PKA-
phosphorylated HSL gets translocated to the lipid droplet where its enzymatic activity is 
induced by perilipin A (46, 47). ATGL gets phosphorylated at some sites as well (by oth-
er unknown kinases) but whether these phosphorylations have an inhibitory or stimulat-
ing effect on its activity remains unclear (21). Only recently, a potent inhibitor of the adi-
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pose triglyceride lipase was identified, the product of the so-called G0/G1 Switch Gene 2 
(G0S2) (48). G0S2 was shown to bind to the patatin domain of ATGL thereby inhibiting 
its TAG hydrolyzing activity. The inhibitory mechanism still hasn’t been described in de-
tail (48). 
 
FIGURE 1.3.1. A model for the regulation of lipolysis. In the basal state, CGI-58 binds to perilipin A and 
locates on the lipid droplet (49, 50). ATGL is either in the cytosol or on lipid droplets and displays only mi-
nimal activity. Inactive HSL and MGL are found in the cytosol. Upon hormonal stimulation, perilipin A gets 
phosphorylated by PKA and releases CGI-58 which now can bind to ATGL and stimulate its activity. Phos-
phorylated HSL translocates from the cytosol to the lipid droplet where it binds to perilipin A and gets acti-
vated. ATGL that is stimulated by CGI-58 and located on the lipid droplet hydrolyzes triglycerides (TG) into 
diglycerides (DG) and fatty acids (FA). Diglycerides are further cleaved by HSL into monoglycerides and fatty 
acids. And finally, MGL catalyzes the hydrolyzation of the monoglyceride into glycerol and fatty acids (51). 
Fatty acids are released into the blood stream. 
 
Mutations in the C-terminal region of ATGL lead to an increased enzymatic activity but 
inhibit its association with lipid droplets. These findings suggest that the C-terminal re-
gion of ATGL interferes with the binding of CGI-58 but is needed for its translocation to 
the lipid droplet (38). The N-terminal hydrophobic stretch in CGI-58, which is rich in tryp-
tophan, has been shown to be necessary for lipid droplet binding and also for stimulating 
ATGL activity although it has no influence on interaction with ATGL (40). Truncated C-
termini in CGI-58 go along with a complete loss of ATGL-activating function but have no 
effect on the localization of CGI-58 (40).  
 
1.4. ATGL-knockout mice (Atgl-/-) 
For functional analysis of ATGL, homozygous null-mice were produced. They suffer from 
generalized metabolic dysfunction (52) and accumulate triglycerides essentially in all 
organs of the body (31). Most of the triglycerides are obviously found in WAT and BAT 
but also in cardiac and skeletal muscle and to a lesser degree in testis, liver, and kidney 
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(22). Compared to wild type littermates, Atgl-/- mice exhibit an increased whole body fat 
mass (and therefore increased plasma leptin levels) but a similar lean body mass at 
identical food intake rates (31). Knockout mice display mild obesity with an increase in 
lipid droplet size and hypertrophy of adipocytes (31). Basal lipolysis is similar in wild type 
and knockout mice but there is a drastic reduction in stimulated lipolysis in mice deficient 
for ATGL (31). FFA release following a hormonal stimulus is reduced by about 75% in 
KO mice (21). As the liver is no longer provided with fatty acids plasma levels of triglyce-
rides, total and HDL cholesterol, and ketone bodies are lowered (21). Since fatty acids 
are no longer available as energy source, uncoupled mitochondrial respiration needed 
for heat production/thermogenesis is defective in brown adipose tissue. KO mice are 
cold-sensitive (22) and die upon exposure to coldness for several hours. Furthermore, 
reduced FFA release leads to an increased glucose uptake as alternative energy supply 
what explains increased glucose tolerance and insulin sensitivity in Atgl-/- mice during 
fasting (52, 53, 54). Moreover, carbohydrate oxidation is increased in KO mice during 
exercise what leads to a depletion of glycogen stores in muscle and liver (54). During 
fasting, the respiratory quotient (RQ) decreases in WT mice due to an increased β-
oxidation but stays elevated in KO mice as they can’t mobilize stored triglyceride for 
energy production (31). This goes along with a decrease in oxygen consumption and 
reduced endurance capacity during running exercises in knockout mice (54). These re-
sults are in line with the fact that ATGL mRNA is upregulated by exercise in healthy 
young men (55). 
The obviously most harmful and in fact mortal phenotype is the fatty degeneration of the 
heart. Due to the massive TG accumulation, the heart weight is increased in Atgl-/- mice 
going along with a thickening of the left ventricle wall and a drastically reduced ejection 
volume (31). The first mice die around the age of 12 weeks from cardiac insufficiency 
and at this age, TG content of the heart is 20-fold increased in comparison to wild type 
mice (31). 
  
 
FIGURE 1.4.1. Isolated hearts of wild type and 
Atgl-/- mice. Left: heart of a wild type mouse. 
Right: heart of a knockout mouse. The yellowish-
white discoloration and increased size result from 
the massive TG accumulation (image source: 
(31)). 
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Since reduced fatty acid release and triglyceride accumulation was observed not only in 
adipose tissue but essentially in every organ of the body (except for the brain), ATGL 
seems to be important for lipolysis everywhere in the organism and its activity obviously 
cannot be compensated by other lipases (31). 
An interesting discovery was that while mutations in CGI-58 provoke the same pheno-
type as mutations in ATGL they also have an effect on the skin permeability barrier func-
tion (41) (56). Therefore, CGI-58 seems to have an ATGL-independent function in the 
skin. CGI-58-KO mice already die within 16 hours after birth (56). 
 
1.5. Human pathology 
Several autosomal recessive mutations that result in a phenotype similar to the one de-
scribed for Atgl-/- mice and are classified as neutral lipid storage disease (NLSD) have 
been described in the human ATGL gene but also in the gene encoding CGI-58 (34). 
Humans deficient for a functional ATGL accumulate triglycerides in various tissues and 
cells like granulocytes (22). The lipid vacuoles inside these white blood cells lead to a 
morphology called Jordans’ anomaly which is one of the diagnostic characteristics for 
NLSD (57). In contrast to KO mice, human patients are not obese. This would suppose 
that ATGL has another, less important function in humans than in mice or that alternative 
lipases exist in humans which can in part replace ATGL activity. However, the hypothes-
es on the exact role of ATGL in human lipid metabolism are still discussed very contro-
versially (58) (59) (60). ATGL-deficient humans suffer from severe cardiac and milder 
skeletal myopathy. To date two patients have died from cardiac insufficiency but contrary 
to KO mice it is not clear if this was caused by lipid accumulation (39, 61): Furthermore, 
a common feature associated with mutations in the ATGL gene is some kind of liver dis-
ease (21, 22). 
Humans with mutated forms of CGI-58 show more or less the same symptoms as de-
scribed above except for an additional phenotype affecting the skin named nonbullous 
congenital ichthyosiform erythroderma (34). Ichthyosis describes the scaly, wrinkled skin 
which can no longer perform its permeability barrier function. Furthermore, defective 
CGI-58 results only in a very mild form of myopathy but displays additional neurological 
disorders (34). Therefore, people having mutations in the gene encoding ATGL suffer 
from neutral lipid storage disease with myopathy (NLSDM) whereas mutations in CGI-58 
cause neutral lipid storage disease with ichthyosis (NLSDI) also called Chanarian-
Dorfman syndrome (CDS) (42). 
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1.6. Docosahexaenoic acid (DHA) 
Docosahexaenoic acid (C22:6n-3; trivial name: cervonic acid) is a ω-3 long chain po-
lyunsaturated fatty acid (LC-PUFA) with a tail of 22 carbon atoms and six double bonds 
(62). It is the main PUFA in the mammalian retina and human breast milk and highly 
concentrated in the brain (62, 63, 64, 65). 
 
FIGURE 1.6.1. Structure of docosahexaenoic acid (DHA). Schematic representation of DHA with its 22 
carbon atoms and six double bonds. The carboxylic acid head group is marked in red (image source: (66)). 
. 
 
DHA is either directly taken up by ingestion of cold water fish oil, alternatively it can be 
synthesized from its precursor α-linolenic acid (ALA; C18:3n-3) (67). Most of the 20- and 
22-carbon PUFAs in human tissue are derived from conversion of C18:2n-6 (linoleic ac-
id; LA) and C18:3n-3 (ALA), respectively (68). α-linolenic acid (ALA) is an essential ω-3 
polyunsaturated fatty acid with a chain of 18 hydrocarbons and 3 double bonds which 
has to be taken up with the diet. It is highly concentrated in vegetable oils (69, 70). There 
exist three different pathways for DHA biosynthesis: one anaerobic (marine bacte-
ria/unicellular eukaryotes) and two aerobic (Δ4-desaturase-dependant (unicellular euka-
ryotes) and Δ4-desaturase-independent (mammals)). (71). In mammals, a pathway in-
volving a peroxisomal retroconversion step, the so-called Sprecher pathway, is at work 
(72). The retroconversion is necessary due to the absence of a specific desaturase, the 
Δ4-desaturase, which was believed for a long time to be present in mammals, too (73). 
This enzyme would be needed for the introduction of one double bond into C22:5n-3. But 
instead, C22:5n-3 first gets elongated and desaturated to C24:6n-3 which is transported 
to the peroxisomes and finally β-oxidized to form C22:6n-3 (64, 73). Patients suffering 
from Zellweger syndrome show reduced DHA brain levels and synthesis rates (67, 70) 
what further indicates that the last steps of DHA biosynthesis take place in peroxisomes. 
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FIGURE 1.6.2. Pathway for DHA biosynthesis in mammals. A, The sprecher pathway for DHA synthesis 
comprises a series of elongations and desaturations. The last (β-oxidation) steps are taking place in the 
peroxisomes. Red marked enzymes were investigated in our study. B, A more detailed view of β-oxidation 
inside peroxisomes (image source (67)). 
 
The main organ for DHA synthesis is the liver where ALA gets converted by a number of 
desaturation and elongation events. After injection of the radioactively labeled precursor, 
DHA appears first in the liver and later in the brain and the retina (62). This suggests that 
the liver secretes DHA into the blood stream in the form of lipoprotein particles (mainly 
acylated in PL) which are taken up by brain and retina and incorporated into cell mem-
branes (62). Liver synthesis rate exceeds the brain consumption rate by about 30 times, 
so the liver is able to “feed” the whole organism with DHA (69). Brain and heart also 
have the capacities to synthesize DHA although compared to the liver the levels of DHA 
produced in the heart are marginal (69). The brain either takes up preformed DHA incor-
porated into phospholipids but it can also synthesize minor amounts itself. DHA biosyn-
thesis in the brain takes place mainly in astrocytes (74). It could be part of the supporting 
role of astroglia to ensure the DHA supply of neurons (63). 
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1.7. Functions of DHA 
Omega-3 and omega-6 FA are mainly incorporated in the inner membrane leaflet of cells 
(neurons, erythrocytes, cardiac myocytes, etc.) at the sn-2 position of phospholipids (75). 
Hydrolytic release of PUFA from this position is catalyzed by the Ca2+-dependant isoform 
of phospholipase A2 (Ca2+-PLA2) which frees them for cell signaling and eicosanoid syn-
thesis (75). Many actions of DHA rely on the fact that it can be transformed to bioactive 
lipid mediators.  
Anti-inflammatory/inflammation resolving mechanisms 
The main omega-6 PUFA is arachidonic acid (AA; C20:4n-6) which is metabolized to 
eicosanoids classified as thromboxanes, prostaglandins, and leukotrienes that fulfill 
mainly important pro-inflammatory actions (76). The most abundant omega-3 PUFA are 
DHA and EPA (C20:5n-3) which have especially anti-inflammatory functions. On the one 
hand omega-3 FA compete with omega-6 FA for the same transport, acylation, and syn-
thesis pathways and for incorporation into cell membranes (77). EPA and DHA are in-
corporated into phospholipid membranes of inflammatory cells in a time- and dose-
dependent manner, partly at the expense of AA, and thereby inhibit AA metabolism and 
the production of AA-derived eicosanoids (76). On the other hand, EPA and DHA serve 
as precursors for the production of anti-inflammatory players like resolvins (E- and D-
series), docosanoids and protectins, especially DHA-derived neuroprotectin D1 (NPD-1) 
(78, 79). DHA/EPA further negatively influence the production of peptide mediators (e.g. 
cytokines) and other inflammatory agents (adhesion molecules, platelet activating factor, 
TNFα,..) because they affect transcription factors that regulate inflammatory gene ex-
pression (NFкB, PPARγ) (78). DHA alters lipid raft organization and function since it is 
stereochemically incompatible with sphingolipids and cholesterol and thereby affects 
these pro-inflammatory signal-transduction pathways that are compartmentalized by 
such lipid rafts (78). PPAR/RXR-heterodimers can be activated already by µmol-
concentrations of DHA and EPA and in turn inhibit NFкB-activation (78). A link between 
PPAR activation and n-3 PUFAs has also been described in another study. They could 
show that PPARβ/δ binding to DNA is increased when primary cultures of rat cardiomyo-
cytes where provided with EPA or DHA and this is attributed to an upregulated ACOT 
(acyl-CoA thioesterase) activity which guarantees high NEFA concentration and there-
fore a constant supply with PPAR ligands (80). Since EPA and DHA are PPAR ligands 
themselves this could be some kind of a positive feedback loop (78). 
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FIGURE 1.7.1. Proposed model of anti-inflammatory actions mediated by EPA and DHA (78). 
EPA/DHA are either incorporated into lipid raft domains or transported into the cell and have several func-
tions: modification of lipid raft organization by EPA/DHA important for signal transduction via TLRs (and/or 
other receptors incorporated into lipid rafts) and further transcription factor activation (e.g. NFκB); alteration 
of nuclear receptor activity (PPAR) thereby inhibiting expression of inflammatory mediators; interference with 
the production of pro-inflammatory metabolites from AA; production of anti-inflammatory metabolites from n-
3 PUFAs. AA, arachidonic acid (C20:4n-6);DHA, docosahexaenoic acid (C22:6n-3); EPA, eicosapentaenoic 
acid (C20:5n-3); NF-kB, nuclear factor kB; IkB, inhibitor of NF-kB; IL, interleukin; PPAR, peroxisome prolife-
rator-activated receptor; PUFA, polyunsaturated fatty acids; TLR, Toll-like receptor; these receptors recog-
nize highly conserved pathogen-associated molecular patterns (PAMPs) and then generate an immune 
response; TNFa, tumor necrosis factor alpha (image adapted from: (78)). 
 
Development and maintenance of the nervous system 
DHA is the ω-3 fatty acid preferentially taken up by the brain where it is incorporated into 
brain phospholipids (especially phosphatidylserine (PS)) - the main constituents of neu-
ronal membranes (63). DHA is important for synaptogenesis/neurogenesis (62, 79), neu-
rotransmitter metabolism (81) and normal brain development (64). It promotes neuroge-
nesis by regulating transcription factors and the cell cycle of neural stem cells (82). 
Moreover, DHA is the major structural component of the gray matter (83) and the major 
fatty acid transported across the placenta during fetal development (62, 81). This might 
be a reason for circulating DHA levels being higher and ALA conversion rates being in-
creased in women during the reproductive cycle (75). Fluidity of synaptic membranes 
increases when DHA is incorporated (due to its stereochemistry (84)) what improves 
learning ability (64). In (passive or active) avoidance tests (to measure learning behavior) 
DHA-fed mice perform better compared to mice on a standard chow-diet (85, 86). DHA 
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incorporated into phosphatidylserine (PS) inside neuronal membranes has an anti-
apoptotic effect because DHA-containing PS preferentially interacts with membrane pro-
teins. Thereby PS accumulates inside nerve cell membranes further facilitating Raf-1 
translocation to the membrane (63). Raf-1 is involved in anti-apoptotic signaling mechan-
isms. That’s possibly why neuronal cells take up that much DHA to retain PS in the 
membranes (63). Another anti-apoptotic effect is the activation of Bcl-2 by NPD-1 (79). 
Bcl-2 also plays a role in regulating the programmed cell death. Since Bcl-2 and Raf-1 
are involved in the same functional processes, there might be a link between these anti-
apoptotic functions. Furthermore, brain phosphatidylethanolamine (PE) plasmalogen 
levels are higher in DHA-fed mice (85). Plasmalogen is important in lowering the ability 
of cholesterol to be oxidized in brain phospholipid bilayers – therefore it is needed for 
maintaining and improving the brain’s function (85). During ischemic injury or convul-
sions, the brain was shown to release free 22:6n-3 which is converted to docosanoids 
that have neuroprotective functions and fight/resolve inflammation (62, 79). 
Patients with generalized peroxisomal disorders (Zellweger syndrome; Refsum’s dis-
ease) have low DHA levels in brain – supplementation with DHA improves many of the 
symptoms: plasmalogen concentration increases in erythrocytes, liver enzymes return 
(almost) to normal, brain myelin normalizes (87).  
Vision 
DHA accumulates in retinal tissues during fetal development where it is needed for pho-
toreceptor membrane biogenesis and represents over 60% of the fatty acids in the outer 
membrane segment of retinal photoreceptor cells (62, 71, 88). There it guarantees visual 
acuity since proper function of rhodopsin has been shown to depend on DHA levels (71). 
Moreover DHA attenuates microglial activation and delays retinal degeneration (89). 
Cardiovascular system 
The anti-arrhythmic functions of DHA/EPA rely on the incorporation into myocardial cell 
membranes where they affect trafficking of channels in lipid rafts and have direct effect 
on the sinus node and depolarization/repolarisation rate (90). The endothelial function 
improves upon DHA-supplementation; furthermore large artery stiffness and blood pres-
sure are reduced. Anti-atherosclerotic functions further rely on the reduction of pro-
atherogenic cytokines and growth factors like interleukins, TNFa, PDGF, and MCP-1 
which is again closely connected with its anti-inflammatory action (90). 
Serum lipids 
TG-reducing properties – maybe due to increased beta-oxidation and reduced lipogene-
sis by regulation of gene expression – are controversially discussed (85, 91). At least for 
EPA it was shown that it increases beta-oxidation when changing from fed to fasted sta-
tus (92).  
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Other functions 
DHA might have anticancer activity since it downregulates SOD-1 gene expression the-
reby enhancing oxidative stress what might be killing cancer cells more effectively (93). 
DHA is likely to have a number of other beneficial functions, especially in the brain. Neu-
rological disorders like depression (71) or Alzheimer’s disease (85) were discussed to be 
closely connected with changes in DHA levels of the brain. Preterm infants not supple-
mented with DHA displayed reduced cognitive development (94). The beneficial func-
tions of DHA seem to be manifold but detailed information on its mode of actions still 
remains elusive. 
 
1.8. Lipid profiling by tandem MS1 
Lipid profiling of Atgl-/- mice by MS/MS without prior HPLC separation revealed some 
interesting new insights into the physiology of ATGL (Ingo E. Streith, unpublished data). 
Phospholipids (PC, PE, PS, PI, and CL) were examined for fatty acid composition in car-
diac muscle, skeletal muscle, liver, WAT, BAT and testis by tandem MS. The results 
showed a significant decrease in DHA-containing phospholipids in the heart of Atgl-/- 
mice (compared to WT and HSL-/- mice) whereas most of C18:0/C18:1/C18:2-containing 
PL species were increased (Fig.1.8.1). This effect was most pronounced for PC and PE 
but was also observed concerning fatty acid composition of PS, PI, and CL. 
 
FIGURE 1.8.1. Lipid profiling analysis by MS/MS. Mass spectrometric analysis of PC composition in 
cardiac muscle of wild type mice and ATGL/HSL deficient mice (absolute values). DHA-containing PC 
species are marked in red. n, number of mice. 
 
Looking at the TAG profile (Fig.1.8.2), again most DHA-containing triglycerides were 
reduced in CM of mice deficient for ATGL compared to wild type mice (C56:7; C58:6; 
C58:9) whereas triglycerides containing linoleic acid (C18:2) were increased (C54:4; 
                                                          
1 All figures in chapter 1.8 provided with courtesy by Ingo E. Streith 
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C54:5). However, it has to be kept in mind that concerning particular triglycerides there 
can be an overlay of many different species (e.g. C58:6 could be composed of 
C22:6/C18:0/C18:0 but also of C20:4/C:20:0/C18:2). For an exact determination of the 
composition of triglycerides a further analyzation step would have been necessary. 
 
 
FIGURE 1.8.2. Quantitative fatty acid composition of TAG species. Fatty acid composition of TAG spe-
cies was investigated in cardiac muscle of WT, Atgl-/-, Hsl-/-, and Cgi-58-/- mice by MS/MS. 
 
The same pattern was obtained for free fatty acids in the cardiac muscle (Fig.1.8.3). 
C22:6n-3 was again decreased in ATGL-deficient mice whereas C18-fatty acids were 
increased compared to wild type mice although these results were not significant due to 
high standard deviations. 
 
FIGURE 1.8.3. FFA composition analyzed by MS/MS. WT, wild type; ATGL, Atgl-/-; HSL, Hsl-/-; WT-CGI, 
wild type with functional CGI-58; CGI, CGI-58-/-. 
 
In summary, precursors of LC-PUFAs incorporated into phospholipids and triglycerides 
were increased in Atgl-/- mice compared to WT mice whereas LC-PUFAs, especially 
DHA,  were reduced.  
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2. Aim of the study 
 
The results of the lipid profiling analysis (chapter 1.8) suggested a causal relationship 
between ATGL deficiency and reduced levels of DHA-containing lipid species. Therefore, 
we wanted to elucidate the role of ATGL in DHA biosynthesis. 
We followed two main approaches both connected to the TG-hydrolyzing activity of 
ATGL: 
• Release of FFA by ATGL could influence signaling pathways/regulate gene ex-
pression, thereby exerting an effect on DHA synthesis 
• ATGL could release those FA from triglycerides/phospholipids that are needed as 
precursors for LC-PUFA synthesis 
Additionally, feedback regulation could have an impact on DHA levels since DHA is a 
PPAR ligand itself. The main approach to answer some of these questions was to com-
pare the mRNA levels of selected enzymes involved in DHA-synthesis in various mouse 
tissues by doing quantitative real-time PCR measurements. DHA (C22:6n-3) is synthe-
sized from α-linolenic acid (C18:3n-3) mainly in the liver but also in the brain and the 
heart (67, 69). The first desaturation and elongation steps take place in the endoplasmic 
reticulum. The C22:5n-3-intermediate produced inside the ER is transported to the pe-
roxisomes where it gets β-oxidized to form DHA (64, 73). We chose following enzymes 
of the DHA-synthesis pathway to take a closer look at: 
- FADS1: fatty acid desaturase 1; Δ5-desaturase 
- FADS2: fatty acid desaturase 2; Δ6-desaturase; rate-limiting enzyme which fulfills 
the first desaturation step 
- ELOVL2: elongation of very long chain fatty acids-like 2; elongase with high sub-
strate specificity for C20:5 and C22:5 
- 17β-HSD4: 17β-hydroxysteroid dehydrogenase type 4; peroxisomal β-oxidation 
enzyme 
FADS1 and FADS2 were selected as they are the rate-limiting enzymes of DHA biosyn-
thesis (68). Furthermore, FADS2 but also ELOVL2 are rather important for this pathway 
as both of them are catalyzing two synthesis steps. 17β-HSD4 was selected as one of 
the peroxisomal enzymes involved in β-oxidation of DHA and has been shown to be es-
sential for DHA synthesis (64). 
The expression of these enzymes was examined primarily in the liver being the main 
organ of DHA synthesis (69) but also in the heart since the changes in DHA-containing 
phospholipid levels were observed in the heart. 
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3. Materials and Methods 
 
MATERIALS 
 
3.1. Plastic- and glassware 
Nuclease/DNA-free 1.5 ml/2 ml PP reaction tubes, 15 ml/30 ml sterile PP tubes with 
screw cap, pipette tips, Petri dishes, sterile serological pipettes, and 96-well microplates 
were purchased from Greiner bio-one (Kremsmünster, Austria), Sarstedt (Nümbrecht, 
Germany) and Corning Inc. (NY; USA). Fast optical 96-well reaction plates for real-time 
PCR were used from Applied Biosystems (United States). Glass vessels, for instance 
beakers, Erlenmeyer flasks, and graduated cylinders, were bought from the company 
Lactan (Graz, Austria). Glassware was washed and autoclaved (121°C) before usage. 
 
3.2. Chemicals 
All chemicals listed, if not indicated otherwise/separately, were purchased from the com-
panies Merck (Darmstadt, Germany), Carl Roth (Karlsruhe, Germany), J.T. Baker (Phil-
lipsburg, NJ, USA) or Sigma Aldrich (St. Louis, MO, USA) and had a purity grade/degree 
of pro analysi (p.a.).   
 
3.3. Radiochemicals 
α-32P-dATP (red) was purchased from Hartmann Analytic GmbH (Braunschweig, Ger-
many) 
 
3.4. Enzymes 
DNaseI/10x DNaseI buffer (Invitrogen) 
Phusion Hotstart DNA-polymerase/5x High Fidelity buffer (Finnzymes) 
Restriction enzyme EcoRI/10x EcoRI buffer (Fermentas) 
T4-DNA-Ligase/appropriate 10x buffer (New England Biolabs) 
Calf Intestine Phosphatase (CIP, New England Biolabs) 
DNA Polymerase I, Large (Klenow) Fragment (New England Biolabs)/Labeling 5x buffer 
(Promega) 
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3.5. Kits 
BCA Protein Assay Reagent (bicinchoninic acid) (Thermo Scientific) 
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
HR series NEFA-HR(2) kit (Wako Diagnostics) 
Maxima™ SYBR Green/ROX qPCR Master Mix (Fermentas) 
Power SYBR® Green PCR Master Mix (Invitrogen) 
 
3.6. Equipment 
ABI PRISM® 310 Genetic Analyzer (Applied Biosystems) 
Accela High Speed LC/UHPLC system (Thermo Scientific) 
Balances (ScalTec) 
Benchtop centrifuge 5415R (Eppendorf) 
Biotrak II Visible Plate Reader (Amersham Biosciences) 
C1000 Thermal Cycler (Bio-Rad) 
Centrifugal vacuum concentrator (ATR Heto) 
Centrifuge GS-6/GS-6R (Beckman Coulter) 
CFX96 Real-Time System (Bio-Rad) 
DNA Engine DYADTM Thermal Cycler (Bio-Rad) 
Dri-Block DB-3 (Techne) 
Electrophoresis Power Supply EPS 600 (Pharmacia Biotech) 
GE Image Quant 3000 (GE Healthcare) 
Horizontal DNA Electrophoresis Gel Boxes (Bio-Rad) 
Model 285 Vacuum Blotter (Bio-Rad) 
Nanodrop ND-1000 (Peqlab) 
Prism 310 Genetic Analyzer (ABI) 
Sample Concentrator (Techne) 
StepOnePlus RT PCR Systems (Applied Biosystems (ABI)) 
STORM 860 Phosphorimager (Molecular Dynamics) 
Test-tube rotator/Rotating wheel (Labinco) 
Thermomixer compact (Eppendorf) 
TriPlusTM Autosampler (Thermo Scientific) 
Trace GC Ultra (Thermo Electron Corporation) 
Trace DSQ Mass Spectrometer (Thermo Electron Corporation) 
Ultra Turrax (IKA works) 
Ultraviolet Crosslinker (UVP Inc.)  
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3.7. Buffers and Solutions 
All buffers and solutions were prepared and/or diluted using “Fresenius” Aqua bidest. 
from Fresenius Kabi (Graz, Austria). For RNA applications ddH2O was treated with 
DEPC. Solutions were autoclaved if they had to be sterile. 
 
3.7.1. Solutions and Stocks 
DEPC-ddH2O 
900 ml ddH2O 
900 µl DEPC (0.1% DEPC) 
autoclaved 
 
0.5M EDTA 
186 g/l 
 
Ethidium bromide 
10 mg/ml ddH2O 
 
IPTG (Isopropyl  
β-D-thiogalactopyranoside) 
23.8 mg/ml ddH2O 
 
X-Gal (5-Bromo-4-chloro-3-indolyl β-
D-galactopyranoside) 
40 mg/ml DMSO 
 
20% SDS 
200 g SDS/l dissolved at 65°C 
 
1000x ampicillin stock 
100 mg/ml 
 
RNase 
10 mg/ml 
Boil for 10 min 
 
 
 
1 M Tris-HCl 
121.1 g Tris 
adjusted to pH 7.5 with HCl 
 
5x DNA loading dye 
3 ml 30% glycerol 
7 ml ddH2O 
25 mg bromophenol blue 
25 mg xylene cyanol 
 
3 M Potassium acetate 
294 g 3 M potassium acetate 
115 ml glacial acetic acid 
 
Hybridization solution 
50 ml 1 M sodium-phosphate buffer 
70 ml 20% SDS 
80 ml ddH2O 
400 µl 0.5 M EDTA pH 8.0 
pH to 7.2 
 
Prehybridization Solution 
Hybridization solution + 1% BSA 
 
1000x protease inhibitor (Pi) 
20 mg leupeptin 
2 mg antipain 
1 mg pepstatin 
dissolved in 1 ml DMSO 
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Sevac 
1.18 M CHCl3 
0.04 M isoamyl alcohol 
DNA: overlaid with ddH2O; RNA: cov-
ered with 0.1 M Tris-HCl (pH 8.0) dis-
solved in DEPC-ddH2O 
 
 
 
Acidic Folch reagent 
20 ml CHCl3 
10 ml MeOH 
1% glacial/pure acetic acid 
 
Lysis Solution 
0.3 M NaOH 
0.1% SDS 
 
TRIzol (Invitrogen): TRIzol® Reagent is a solution containing phenol and guanidine iso-
thiocyanate and was used for isolating total RNA from cells and tissues by phenol-
chloroform extraction. Phenol-chloroform extraction relies on phase separation by centri-
fugation. 
 
RNase away (Molecular Bioproducts): RNase away is an alkali hydroxide solution used 
as a surface decontaminant to remove nucleases. 
 
3.7.2. Buffers 
50x TAE buffer 
242 g Tris-HCl 
57.1 ml CH3COOH 
100 ml 0.5 M EDTA 
ddH2O to 1 l, pH to 8.0 
 
10xMOPS 
21 g MOPS  
3,6 g NaOAc 
10 ml EDTA (0.5M) 
DEPC-H2O to 500 ml 
pH to 7.0 (10N NaOH) 
 
1 M sodium-phosphate buffer, pH 7.0 
57.7 ml 1 M Na2HPO4 
42.3 ml 1 M NaH2PO4 
 
 
1x TE buffer 
10 mM Tris pH 7.4 
1 mM EDTA pH 8.0 
 
HSL buffer 
0.25 M sucrose 
1 mM EDTA 
1 mM DTT 
to pH 7.0 with acetic acid 
 
20xSSC 
3 M NaCl 
0.3 M C6H5O7Na3•2H2O (trisodium ci-
trate dihydrate) 
ddH2O to 1 l, pH to 7.0 
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Lysis Buffer I 
5 ml 1 M glucose 
2.5 ml 1 M Tris-HCl (pH 7.5) 
2 ml 0.5 M EDTA 
90.5 ml ddH2O 
Lysis Buffer II 
0.2 ml 10 M NaOH 
0.5 ml 20% SDS 
9.3 ml ddH2O 
 
3.8. Media 
Media were sterilized by autoclaving at 121°C and stored at 4°C. 
 
LB medium 
10 g peptone 
5 g Yeast Extract 
10 g NaCl 
ddH2O to 1 l, pH to 7.0 
 
LB-agar plates 
10 g peptone 
5 g Yeast Extract 
10 g NaCl 
ddH2O to 1 l, pH to 7.0 
15 g agar agar 
 
3.9. Standards 
GeneRulerTM 1kb DNA ladder (Fermentas) 
MassRulerTM Low Range DNA ladder (Fermentas) 
 
3.10. Primers 
Primers were designed using Harvard PrimerBank (95) (96) (97), NCBI Primer-BLAST 
and Primer Designer, version 2.0 (Scientific & Educational Software, NC, USA) and pur-
chased from Invitrogen or Eurofins MWG Operon. 
 
Gene Forward primer (5’ → 3’) Reverse primer (5’ → 3’) Length (bp) 
Amplicon 
(bp) 
NCBI 
Gene ID 
mFads1 agcacatgccatacaaccatc tttccgctgaaccacaaaataga 21/23 110 76267 
mFads2 aagggaggtaaccagggagag ccgctgggaccatttggtaa 21/20 150 56473 
mElovl2 tctggtggtgtgttttgaactg acaggccgtagtaggagtaca 22/21 102 54326 
m17β-
Hsd4 aggggacttcaagggaattgg gcctgcttcaactgaatcgtaa 21/22 112 15488 
mActb agccatgtacgtagccatcca tctccggagtccatcacaatg 21/21 81 11461 
mFads1-
probe ttgaattcacaacatcagcgacttcagc ttgaattcgcggcatgtaagtgaagaag 28/28 810 76267 
mFads2-
probe ttgaattcggagaagatgctacggatgc ttgaattcggctctccaggaacctgata 28/28 802 56473 
 
TABLE 3.1. Sequences of forward and reverse primers designed for real-time PCR and Northern blot 
probe preparation. Underlined sequences represent EcoRI restriction site. 
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3.11. Plasmids 
 
pBluescript II SK+: 
ampicillin resistance (100µg/ml) 
blue/white screening 
general cloning vector 
 
3.12. Animals 
Mice were housed under standard conditions (24°C; 14h light/10h dark) and had free 
access to water and the standard laboratory chow diet (ssniff® M-Z Extrudate; 4.5% w/w 
fat). For some experiments mice were fasted for 12 hours (o/n) or chow diet was sup-
plemented with 0.1% of the synthetic PPARα agonist WY14,643 (Cayman Chemical 
Company) for three weeks. Atgl-/- mice (Pnpla2tm1Rze/Pnpla2tm1Rze) were generated by 
targeted homologous recombination (Fig.3.12.1) (31).  
 
FIGURE 3.12.1. Targeting strategy for generating Atgl-/- mice (31). Murine gene encoding ATGL was 
knocked out by homologous recombination. Depicted at the bottom is the site-specific cassette introducing a 
neomycin resistance and disrupting the ATGL coding sequence (image source: (31)).  
 
Heterozygous mice were bred for the deleted allele. Experimental KO mice were gener-
ated by breeding Atgl+/- or Atgl-/- males to Atgl+/- females. Male offspring was used at 8 to 
maximum 10 weeks of age and backcrossed at least 5 times on the C57BL/6J back-
ground (31). Transgenic mice overexpressing Atgl-cDNA specifically in cardiac muscle 
were generated as described (98). Liver-specific adenoviral expression of ATGL in Atgl-/- 
mice was performed as illustrated (99). 
Animals were killed by cervical dislocation between 8 and 12 a.m., and liver, heart, and 
brain tissues were collected. All experiments were performed with male mice. 
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METHODS 
In the following, ddH2O refers to the Aqua bidest. From Fresenius Kabi. 
 
3.13. Real-time PCR 
 
3.13.1. Primers 
Primers were dissolved in an appropriate volume of ddH2O (as indicated in the instruc-
tions) to a final concentration of 200 pmol/µl by placing them on a thermomixer at 500 
rpm and 37°C for about half an hour. 2 and 4 µl of dissolved primers were loaded on a 
1.5% agarose gel to check the actual concentration. Depending on the intensity of the 
bands, primers were diluted until forward and reverse primers were equally concen-
trated. This was of especial importance for quantitative real-time PCR. 
3.13.1.1. Agarose gel electrophoresis 
Agarose (Invitrogen) was dissolved in 1xTAE (1%: 3 g/300ml; 1.5%: 4.5 g/300ml), boiled 
in the microwave, cooled down to approx. 60°C and mixed with ethidium bromide. For 
polymerization, the gel was poured into the tray fixed in the gel caster. The electrophore-
sis chamber was filled with 1×TAE, the polymerized gel was added and the samples 
(mixed with 5x DNA loading dye) were loaded on the gel. 
  
3.13.2. RNA preparation 
For the handling with RNA it is very important to be as RNase-free as possible. There-
fore everything was done wearing gloves, working benches were cleaned with RNase-
away and water was treated with DEPC. 
DEPC-ddH2O: diethylpyrocarbonate added to double distilled water inactivates RNases 
by covalent modifications. The flask containing DEPC-ddH2O was placed into the hood 
overnight with the lid not screwed down so that DEPC volatilized overnight and was au-
toclaved the next day. 
 
3.13.2.1. Tissue isolation 
Blood samples were collected under anesthetic by puncture of the retrobulbar venous 
plexus. Mice were killed by cervical dislocation. Liver, heart, and brain were dissected 
and immediately transferred into a reaction tube containing TRIzol®. If not used imme-
diately, tissue was kept in cryovials in liquid nitrogen at about -210°C.  
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3.13.2.2. RNA isolation 
The isolated tissue was weighed and 1 ml TRIzol® (Invitrogen) was added for up to 100 
mg tissue, 2 ml were used for more than 100 mg tissue. TRIzol works by maintaining 
RNA integrity during tissue homogenization, while at the same time disrupting and break-
ing down cells and cell components. Guanidinium thiocyanate denatures proteins, includ-
ing RNases, and separates rRNA from ribosomes. The tissue was homogenized with an 
Ultra Turrax (samples not being handled with were kept on ice in the meantime) and in-
cubated at room temperature for 5 minutes. 0.1 ml 1-bromo-3-chloropropane (instead of 
chloroform – less toxic) were added per ml TRIzol® and tubes were mixed vigorously. 
Samples were incubated at RT for another 15 minutes and in the meantime were shaken 
from time to time. Next, they were centrifuged for 15 min at 4°C and maximum 12,000×g. 
The solution then had separated into three distinct phases: an upper aqueous phase 
containing the RNA, an interphase containing the proteins (visible as a white precipitate), 
and the lower organic phase (reddish) containing the DNA. The aqueous phase was 
transferred into a fresh reaction tube. 0.5 ml isopropanol were added per ml TRIzol®, 
mixed vigorously and incubated at RT for 10 minutes. The samples were centrifuged at 
4°C and maximum 12,000×g for 10 minutes. The supernatant was removed and 1 ml 
75% EtOH was added to the pellet. The pellet was washed at 4°C and maximum 7500×g 
for 5 minutes. The supernatant was again removed and the pellet was air-dried until the 
smell of ethanol had vanished completely. The pellet was resuspended in 100 – 600 µl 
DEPC-ddH2O (depending on the size and the RNA concentration). 
 
3.13.2.3. RNA concentration 
For determination of RNA concentration, samples were measured with NanoDrop 1000 
spectrophotometer. Therefore, 1 µl of each resuspended pellet was loaded on the Na-
noDrop. Each sample was measured at least twice. RNA can be quantified using absorp-
tion of light at 260 and 280 nm (A260/280). Ideally, this ratio should be close to 2 for high 
quality nucleic acid. For RNA, an absorption value of 1 equates a concentration of 40 
µg/ml whereas for DNA an absorption of 1 is equivalent to a concentration of 50 µg/ml. 
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FIGURE 3.13.1. Spectrogram showing the maximum absorbance of several substrates (source: (100)). 
With the determined concentration, volume of concentrated RNA needed for 50 µl of a 
0.2 µg/µl-solution was calculated and prepared for every sample (c1∗V1 = 0.2 µg/µl*50µl 
→ c1: measured concentration, V1: volume of the sample needed for preparation of the 
0.2 µg/µl-solution). 2 µl of all diluted samples were merged in a separate reaction tube as 
negative control (a so-called “RT minus sample”) for qRT-PCR. 
 
3.13.2.4. RNA agarose gel electrophoresis 
For examination of RNA quality, isolated RNA samples were denatured and visualized 
on an agarose gel. Due to the nature of RNA, the separation on gels is a bit different 
compared to DNA. RNA that is usually single stranded can fold up itself to form stable 
secondary structures (such as hairpins). This is a problem when you need to separate 
RNA on a gel. Therefore RNA was denatured by incubating with formaldehyde at 55°C. 
1% RNA agarose gel 
3 g agarose were dissolved in 250 ml DEPC-H2O, heated in the microwave until the aga-
rose had completely dissolved and cooled down to approx. 60°C. 30 ml 10xMOPS and 
17.5 ml 37% formaldehyde were added. The gel equipment was washed with 20% SDS 
and DEPC-H2O before usage to destroy any nucleases. The gel was prepared under the 
fume hood about 1 hour before loading the samples because of the formaldehyde. Ethi-
dium bromide had not to be added to the gel since there was enough contained in the 
sample buffer. 
RNA sample preparation 
5 µg RNA (200 ng/µl) were mixed with 6 µl 5xRNA sample buffer and filled up with 
DEPC-ddH2O to 30 µl. The samples were denatured for 15 min at 55°C. They were 
loaded on the gel and the gel was run for 20 min at constant 90 V. 1xMOPS was used as 
running buffer. 
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3.13.2.5. DNase digest 
If the quality of RNA was good, RNA samples were digested with DNase I to destroy any 
unwanted DNA-contamination. For the DNase digest a kit from Invitrogen was used. 
 µl 
RNA (=1µg*) 5 
DNase 1 
10xDNase-buffer 1 
DEPC-H2O 3 
*5 µl of the prepared 0.2 µg/µl-dilutions → equivalent to 1 µg RNA 
 
A mastermix was prepared containing DNase, buffer and water (on ice!). 5 µl of the mas-
termix were pipetted into reaction tubes, 5 µl RNA were added and samples were incu-
bated for 15 min. at RT and 350 rpm in a thermomixer. DNaseI was inactivated by addi-
tion of 1 µl 25 mM EDTA and incubation at 65°C for 10 minutes. Samples were kept on 
ice afterwards. 
 
3.13.2.6. Reverse transcription 
The DNase-digested samples were immediately subjected to reverse transcription with a 
kit from Applied Biosystems since cDNA is much more stable than RNA. 
 µl 
10x RT-buffer 2 
dNTPs (100mM) 0,8 
10x Random Primer 2 
Reverse transcriptase 1 
RNase inhibitor 1 
H2O 3,2 
 
A mastermix was prepared for all samples except the RT minus sample. For the RT mi-
nus sample the reverse transcriptase was excluded, instead 1µl of water was added. The 
RT minus sample was used during real-time PCR as a control to know if DNase-digest 
worked and to see potential DNA contaminations. The mastermixes were pipetted into 
PCR strips and the DNase-digested samples (11µl) were added. Reverse transcription 
was performed in the 1000 Thermal Cycler from BioRad using following protocol: 
 Step1 Step2 Step3 Step4 
Temperature 25°C 37°C 85°C 4°C 
Time 10min 120min 5min Forever 
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3.13.3. Quantitative Real-Time PCR 
Real-time PCR was performed using the CFX96 real-time PCR detection system com-
bined with the 1000 Thermal Cycler (Bio-Rad) or using the StepOnePlus RT-PCR sys-
tem (ABI). 
SYBR Green is a fluorescent dye that binds double-stranded DNA like EtBr but with 
much higher sensitivity. In real-time PCR, a very simple principle is followed: the more 
target-mRNA was expressed in the various tissue samples, the more cDNA should be 
obtained by reverse transcription, the more SYBR Green should bind to the cDNA and 
the earlier the fluorescence measured during real-time PCR should reach a certain thre-
shold. This happens at a specific cycle what determines the threshold cycle value or 
Ct-value. 
 
3.13.3.1. Optimal primer concentration 
For determination of the concentration of forward and reverse primer resulting in a suffi-
cient template amplification rate, three different primer concentrations were tested: 
0.5 µl (c=10 pmol/µl in 20 µl → 100 pmol) = 250 nM 
1.0 µl (200 pmol) = 500 nM 
1.5 µl (300 pmol) = 750 nM 
For this primer testing a 1:25-dilution of the 50 ng/µl-stock of a WT cDNA-template was 
used and three different mastermixes were prepared: 
MM 1 (× 𝒙)   MM 2 (× 𝒙)   MM 3 (× 𝒙) 
- 10 µl SYBR Green   - 10 µl SYBR Green  - 10 µl SYBR Green 
- 4 µl cDNA    - 4 µl cDNA   - 4 µl cDNA  
- 5 µl H2O   - 4 µl H2O   - 3 µl H2O 
𝒙...number of primer pairs to test multiplicated with 3 (for triplicates). For blank mea-
surements, 4 µl ddH2O (BL) or RT minus probe (RT-) were added instead of cDNA. 
Either 19µl (MM1), 18µl (MM2/blank) or 17µl (MM3) of the mastermixes were pipetted 
into a 96-wells microtiter-plate first and 0.5 µl, 1 µl or 1.5 µl of each forward and reverse 
primer were added to MM 1, MM 2/blank or MM 3, respectively. The products of the real-
time PCR were loaded on a 1.5% agarose gel together with a 100 bp-DNA-ladder to veri-
fy the expected and therefore correct size. Furthermore, the amount of product obtained 
using the different primer concentrations was compared on the gel and the lowest primer 
concentration resulting in a sufficient amplification and a threshold Ct-value in a range of 
20 to 25 was chosen for further analyses. 
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Melt curve analysis was performed to see whether the primers build dimers (if negative 
controls produce a melt curve peak) or amplify unspecific products (melt curve with 2 
peaks). 
 
3.13.3.2. Cycle sequencing 
The real-time PCR products from the primer concentration test run were used for a cycle 
sequencing reaction to check if the amplified gene fragments had the correct sequence. 
This chain-termination method requires a single-stranded DNA template, a primer, a 
DNA polymerase, all four of the standard deoxynucleotides (dATP, dGTP, dCTP and 
dTTP) and four dideoxynucleotides (ddATP, ddGTP, ddCTP, or ddTTP). The dideox-
ynucleotides are the chain-terminating nucleotides which lack a 3’-OH group that would 
be needed for the formation of a double bond between the nucleotides. Thereby DNA 
strand extension is terminated and results in DNA fragments of varying length. All four 
dideoxynucleotides are labeled with fluorescent dyes with different wavelengths of fluo-
rescence and emission. This enables sequencing in a single reaction and is called Dye-
terminator sequencing. 
 
FIGURE 3.13.2. Schematic view of the cycle sequencing reaction (image source: (101)).  
 
cDNA concentration of the PCR products was measured with NanoDrop 1000 and 50 
ng/µl-dilutions were prepared for every sample. 
 
For sequencing, BigDye® Terminator v3.1 Cycle Sequencing Kit was used. 
BigDye v3.1  2 µl 
5x Sequencing Buffer  2 µl 
Primer  5pmol 1 µl 
DNA template 
PCR product: 
Plasmid: 
 
10-50 ng 
150-300 ng 
x µl 
ddH2O ad 10 µl x µl 
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Four batches were mixed for every PCR product, two containing the forward and two the 
reverse primer. 
 
PCR program: 
 1 2 3 4 5 
Temperature 96°C 96°C 53°C 60°C 4°C 
Time [min] 1:00 0:15 0:30 1:30 ∞ 
  30 repeats  
 
1…initial denaturation 
2…denaturation 
3…annealing 
4…elongation/extension 
 
Purification 
2.5 µl 125 mM EDTA and 25 µl 100% EtOH were added to the PCR products. The sam-
ples were transferred into 1.5 ml reaction tubes and centrifuged for 20 min. at 13,000 
rpm (Eppendorf 5415R) and 4°C. The supernatant was removed and samples were 
washed two times with 250 µl 70% EtOH for 15 min. at 13,000-15,000 rpm and 4°C. The 
pellets were dried in the SpeedVac concentrator, dissolved in 15 µl HiDye formamide 
and transferred into PCR tubes. The PCR products were sequenced with the ABI 
PRISM® 310 Genetic Analyzer and the resulting sequences were blasted against the 
mouse genome. 
 
3.13.3.3. PCR efficiency 
The PCR efficiency had to be tested for every gene. Therefore, a dilution series (1:5, 
1:25, 1:125, 1:625) was prepared from a pool of all cDNA samples, the relative expres-
sion of all genes was measured in these diluted, pooled samples and a straight calibra-
tion line was created. This served multiple purposes. For every gene the highest sample 
dilution resulting in Ct-values between 20 and 25 was determined. The standard equa-
tion (y=kx+d;k, slope) was calculated for different thresholds. Finally, the threshold, that 
resulted in a coefficient of determination (R2) of at least 0.997 and a slope as close to -
3.32 as possible, was chosen. A slope of -3.32 indicates a PCR reaction that is 100% 
efficient. Slopes that are more negative than -3.32 indicate reactions with less than 100% 
efficiency. Slopes that are more “positive” than -3.32 may be caused by bad sample 
quality or pipetting problems. Reactions with 100% efficiency result in a 10-fold increase 
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of the PCR amplicon every 3.32 cycles during the exponential phase of amplification 
(log2 10 = 3.3219) (102). The coefficient of determination close to 1 indicates that the 
fluorescence decreases exponentially with the higher degree of dilution. 
 
The dilutions were prepared from the pooled aliquots of the 50 ng/µl-stocks: 
 Dilution Concentration [ng/µl] [ng cDNA/4µl] 
V1 1:5 10 ng/µl 40 ng 
V2 1:25 2 ng/µl 8 ng 
V3 1:125 0.4 ng/µl 1.6 ng 
V4 1:625 0.08 ng/µl 0.32 ng 
  
A separate mastermix was prepared for every single target gene. 
 
MM 
- 10µl SYBR Green 
- 0.5-1.5µl primer forward 
- 0.5-1.5µl primer reverse 
- 3-5 µl H2O 
Wells were preloaded with 16 µl of the mastermix and 4 µl of cDNA were added. For 
statistical reliability at least duplicates should be measured for every dilution. The straight 
calibration line (so-called “real-time PCR standard curve”) was created by plotting the 
logarithm of input nucleic acid (amount of cDNA) on the x-axis and the associated Ct-
values on the y-axis.  
 
3.13.3.4. Housekeeping Gene 
Housekeeping genes are genes involved in basic functions needed for the sustenance of 
the cell. Therefore they are constitutively expressed (they are always turned ON). 
The PCR efficiency of the housekeeping gene has to be consistent with the efficiency of 
the target gene and the threshold Ct-values should be similar. If the efficiency is not the 
same, the amplification rate is different, too. Therefore the values are no more quantita-
tive and mRNA-expression of the target gene can no longer be related to the expression 
of the housekeeping gene. 
 
3.13.3.5. Measurement of the samples 
As the optimal primer concentrations and template dilutions have been ascertained and 
the best-fitting housekeeping gene has been chosen, samples were measured. Real-
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time PCR is used to compare the expression of specific genes (target genes) under spe-
cial conditions (e.g. deficiency of a lipase (KO)) with the expression of these genes under 
“normal” reference conditions (e.g. functional lipase (WT)). For comparison it is neces-
sary to normalize the relative mRNA levels of the target genes in every sample to the 
levels of a housekeeping gene in the same sample since housekeeping genes principally 
are expressed at same levels in all tissues/under all conditions. 
For reliability, 6 batches were prepared for every sample (target sample or reference 
sample) to have one triplicate for target gene expression and one triplicate for house-
keeping gene expression. The mastermixes were prepared the same way as described 
for the PCR efficiency test run. 
 
Quantitative Real-Time PCR protocol (Bio-Rad CFX96) 
 1 2 3 4 
Plate 
R
ead 
5 (Melt Curve) 
Temperature 50°C 95°C 95°C 60°C 45°C – 85°C (in-crement 0.5°C) 
Time [min] 2:00 10:00 0:30 1:00 5:00 
  40 repeats   
 
1...UDG pretreatment for carryover decontamination; OPTIONAL 
2...initial denaturation 
3...denaturation 
4...annealing/extension 
 
3.13.3.6. Evaluation 
For relative quantification the Ct value obtained for the respective target gene of each 
sample had to be related to the corresponding Ct value of the housekeeping gene to 
obtain a standardized ΔCt-value. 
ΔCt = Ct (Target Gene x (Sample y)) – Ct (Housekeeping Gene (Sample y)) 
 
For the comparison of mRNA expression of the samples of interest (e.g. knockout) with 
mRNA expression of the reference samples (e.g. wild type), all ΔCt-values were norma-
lized to the mean reference ΔCt-value. 
ΔΔCt = ΔCt – Mean ΔCt (reference) 
 
The relative mRNA expression levels which actually were compared in the resulting dia-
grams were obtained by following equation: 
Relative mRNA expression levels: 2- ΔΔCt
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3.14. Northern Blot 
 
A northern blot enables the visualization of (target gene) (m)RNA in various tissues by 
labeling with a radioactive probe specifically binding to this RNA. 
 
3.14.1. Preparation of Northern blot probe I 
3.14.1.1. PCR 
For amplification of a specific probe a PCR was done with the primers designed for real-
time PCR. Liver cDNA from wild type mice was used as a template. First, a temperature 
gradient was applied to establish the optimal annealing temperature resulting in the most 
specific and abundant product. In a 2nd PCR, multiple batches were run at this tempera-
ture for each gene to obtain enough cDNA for the Northern blot probe. 
 
PCR-batch (30 µl): 
cDNA template 1 µl 
Primer fwd 0.5 µl 
Primer rev 0.5 µl 
dNTP 0.5 µl 
Phusion polymerase 0.3 µl 
5x High Fidelity buffer 6 µl 
ddH2O 21.2 µl 
 
PCR-Program: 
 1 2 3 4 5 6 
Temperature 98°C 98°C variable 72°C 72°C 4°C 
Time [min] 2:00 0:30 0:30 0:30 10:00 ∞ 
  36x   
 
The PCR products (mixed with a dye) were loaded on a (depending on the size of the 
amplicon) 1% or 1.5% agarose gel together with an appropriate DNA ladder. The gel 
was run at 90V for about 45 minutes and specific products were cut out of the gel with a 
sterile scalpel and purified. 
 
3.14.1.2. Elution of DNA from an agarose gel (“Freeze & Squeeze”) 
Gel pieces were frozen at -70°C for 10 min. or alternatively at -20°C o/n. For melting the 
gel, tubes were placed at 65°C for 5 minutes. With a yellow pipette tip the gel was 
squeezed and transferred into Ultrafree-MC centrifugal filter units with microporous 
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membrane (Millipore, Bedford, USA). The gel pieces were centrifuged for 20 min. at 
8,000 rpm (Eppendorf 5415R), RT. DNA was contained in the eluate at the bottom after-
wards. The volume of the eluate was estimated. For precipitation of DNA 1/10 of the vo-
lume of potassium acetate (3 M; pH 4.8) and the double of the volume of 100% ethanol 
were added. Tubes were placed at -20°C o/n (or alternatively at -70°C for 30 minutes). 
DNA got pelletized by centrifugation at 13,000 rpm and 4°C for 30 minutes. The pellet 
was washed with 600 µl of 70% ethanol and dried for max. 5 min. in the SpeedVac con-
centrator. Depending on its size the pellet was dissolved in 10 to 20 µl of ddH2O. For 
determination of the concentration 1 µl of the resuspended DNA was loaded again on a 
1% or 1.5% agarose gel together with a ladder designed for both DNA sizing and quanti-
fication.  
 
3.14.2. Preparation of Northern blot probe II 
New primers were designed (with Primer Designer, version 2.0) to amplify a piece of 
DNA of about 800 bp for higher specificity. Furthermore, EcoRI restriction sites were 
attached to the 5’ end of the forward primer and the 3’ end of the reverse primer to be 
able to clone the PCR product into a Bluescript vector to get a purified probe in a high 
copy number for Northern blotting. 
First, PCR was run as described before. PCR products were purified from the gel again 
by the “Freeze and Squeeze” method and resuspended in 20 µl ddH2O. As a control 1 µl 
of the DNA was loaded on an agarose gel as before. Next, insert (probe) and vector 
(pBluescript II SK+) were both digested with EcoRI.  
 
3.14.2.1. Restriction digestion 
Insert (30 µl) 
19 µl cDNA 
1 µl EcoRI 
3 µl 10x EcoRI buffer 
7 µl ddH2O 
 
Vector (25 µl) 
2 µl Blueskript 
1 µl EcoRI 
2.5 µl 10x EcoRI buffer 
19.5 µl ddH2O 
Insert and vector were digested for 2 hours at 37°C. The vector was additionally incu-
bated with 1 µl of CIP at 37°C for half an hour. Calf intestinal phosphatase (CIP) inhibits 
the vector’s religation by removal of the 5’ phosphate groups. 
Digested insert was filled up with ddH2O to 100 µl and purified by a chloroform-phenol-
extraction. First 75 µl CHCl3 and then 100 µl phenol were added to the sample with mix-
ing in between (vortex mixer). For phase separation the mix was centrifuged at 13,000 
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rpm (Eppendorf 5415R) for 5 min. at RT. 80 µl of the upper phase were mixed with 8 µl 
potassium acetate (3 M, pH 4.8) and 160 µl 100% ethanol and DNA was precipitated at -
20°C o/n. The digested vector was loaded on a 1% agarose gel, cut out and eluted from 
the gel as described before and was also precipitated o/n. Both, vector and insert were 
pelletized the next day by centrifugation (see “Freeze and Squeeze”) and dried pellets 
were dissolved in 15 µl ddH2O. The resuspended pellets were desalted for half an hour 
by pipetting them onto mixed cellulose esters membrane discs (MF-Millipore™ Mem-
brane Filters) which floated on the water surface of ddH2O-filled Petri discs.  
 
3.14.2.2. Ligation and transformation 
1 µl of desalted vector and insert were loaded on an agarose gel (1%) to determine their 
concentration. 3 times as much insert as vector was used for the ligation. The appropri-
ate volumes of insert and vector were mixed with 1 µl T4 ligase and 1.5 µl ligase buffer, 
filled up with water to a total volume of 15 µl and incubated for 2 hours at RT. 
In the meantime, LB-agar plates were prepared. Therefore, LB-medium mixed with agar-
agar was autoclaved. After cooling down, 1x ampicillin (1000x), 1x IPTG (2000x), and 1x 
X-Gal (2000x) were added and agar was poured into sterile Petri dishes. 
For the transformation 5 µl ligation batch were added to 25 µl chemically competent E. 
coli (DH5T1R cells, Invitrogen) and put on ice for half an hour. Next the cells were heat-
shocked at 42°C for 30 seconds and again cooled-down on ice. Then 200 µl of pre-
warmed LB medium were added, the cells were transformed for 1 hour at 37°C and final-
ly plated on the prepared Petri dishes. The plates were incubated o/n at 37°C (agar side 
on top). 
 
3.14.2.3. Smale-scale preparation of plasmid DNA (“Mini prep”) 
Colonies having an insert were white since the multi-cloning side (MCS) of the Bluescript 
vector is inside the LacZ encoding sequence and insertion into the MCS disrupts this 
sequence. Each white colony was inoculated into 5 ml LB-Amp-medium and shaken at 
37°C o/n. The overnight cultures were cooled on ice and centrifuged for 10 minutes at 
3,500 rpm (Beckman GS-6R) and 4°C. The supernatant was removed, the pellets were 
carefully resuspended in 200 µl lysis buffer I and transferred into a 1.5 ml reaction tube. 
The resuspended cells were mixed with 200 µl freshly prepared lysis buffer II and incu-
bated for 5 minutes at RT. After the addition of 150 µl 3 M potassium acetate, tubes were 
incubated at 4°C for 10 min. so that a white precipitate formed. For removal of the preci-
pitate cells were centrifuged for 5 min. at 13,000 rpm (Eppendorf 5415R) and 4°C. The 
supernatant was moved into a new 1.5 ml reaction tube and extracted by addition of 400 
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µl phenol and 250 µl Sevac. For phase separation the tube was spun for 2 min. at 4°C 
and 13,000 rpm (5415R). The upper aqueous phase containing the DNA was transferred 
into another tube, mixed with 800 µl 100% EtOH and DNA was precipitated by incubation 
at -20°C for 30 min. The plasmids got pelletized by centrifugation at 13,000 rpm and 4°C 
for half an hour and pellets were washed with 400 µl 80% ethanol for 5 min. and 4°C at 
full speed (5415R). The supernatant was removed and pellets were dried in the Speed-
vac. The pellets were dissolved in 48 µl ddH2O mixed with 2 µl RNase (2.5 mg/ml) and 
incubated at 37°C for 15 minutes. 
 
3.14.2.4. Control digest 
For determination of positive clones, 3 µl of recovered plasmids were digested with Eco-
RI as described previously and loaded on a 1 % agarose gel. For clones containing an 
insert, the remainder of the dissolved pellets was also digested with EcoRI, separated on 
an agarose gel, purified by the Freeze and Squeeze method and 15 ng were used for 
labeling with radioactivity.   
 
3.14.3. Blot 
3.14.3.1. Denaturing RNA agarose gel 
RNA agarose gel and samples were prepared as described before. A bit of the agarose 
gel was kept at 55°C for later on. 10 µg of RNA mixed with the denaturing RNA dye were 
loaded on the gel. The gel was run for 1 and a half hour at 90V to get good separation of 
the RNA. Gel was checked under UV for RNA integrity and to see whether the same 
amount of RNA was loaded on the gel. 
 
3.14.3.2. Blotting 
After electrophoresis the agarose gel was placed into a plastic bowl and rinsed with 
ddH2O for 20 to 30 minutes to get rid of the formaldehyde. After drying it (especially the 
slots), the slots were filled with the rest of the agarose gel. RNA was blotted on a mem-
brane by vacuum blotting. Therefore, blotting paper was trimmed, layed in the vacuum 
blotter and dampened with 10xSSC. The blotting paper was covered with the nylon 
membrane (Hybond-N+; Amersham Biosciences) which was 1 cm longer and broader 
than the gel. Both, paper and membrane, were examined for and freed from airbubbles. 
Onto the membrane, a plastic foil was deposited which left open a cutout a bit smaller 
than the size of the gel. The gel was placed on the top and overlapped with the foil by 
about 1 cm. The vacuum pump was turned on (the under-pressure should not exceed 5 
mm Hg), 1.5 l 10xSSC were added to the vacuum blotter and the gel was blotted o/n. 
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Next day, membrane was dried, trimmed and marked by cutting off the upper right cor-
ner. Blotted RNA was crosslinked with the membrane by UV-light in an ultraviolet cros-
slinker with 1200 kcal on the upper side and 600 kcal on the bottom side. The membrane 
was stored in a 50 ml tube with screw cap in the fridge at 4°C. 
 
3.14.3.3. Labeling 
For prehybridization, 1% BSA was added to an appropriate volume of the hybridization 
solution. For 50 ml tubes, 6 ml of prehybridization solution were needed. The plastic 
screw caps had to be punctured with a needle in the middle to prevent an elevated vapor 
pressure during heating. The plastic tubes were placed into hybridization glass tubes and 
incubated with the solution for 4 to 6 hours at 65°C in the hybridization oven (while per-
manently rotating). In the meantime the probes got labeled with 32P.  
For a small blot 15 ng of probe/DNA were used, filled up with water to 15 µl, denatured at 
99°C for 5 min and immediately put on ice afterwards. Following reagents were added to 
the denatured cDNA for radioactive labeling: 
Denatured probe + ddH2O 15 µl 
Nucleotide mix (CTG) 1 µl 
10x BSA 1 µl 
5x labeling buffer 5 µl 
Klenow polymerase 0.5 µl 
32P-dATP 2.5 µl 
 
The mix was incubated for 2 to 3 hours at room temperature. Then the probe was puri-
fied by size exclusion. Therefore a Pasteur pipette was plugged with glass wool and filled 
with Sephadex beads suspended in 1x TE-buffer. First the column got equilibrated with 
500 µl 1x TE, then the probe was loaded on the column and washed off the column with 
200 µl-fractions of 1x TE. Fractions were measured with a hand-held Geiger-Mueller 
counter to know which ones contained the probe. Labeled probes were eluted in the first 
peak. Loading of the column was continued until a second peak (containing the nucleo-
tides) was measured. The 3 to 4 fractions that contained most of the radioactivity (from 
the first peak) were pooled, denatured for 5 min. at 99°C and cooled down on ice. The 
probe was added to the prehybridization solution and the blot was incubated o/n at 65°C 
in the rotating oven. 
 
3.14.3.4. Washing and screening 
Next day the hybridization solution was drained. The membrane was slewed in 2x 
SSC/0.1% SDS and washed for 20 to 30 min. in 1x SSC/0.1% SDS first and then in 0.5x 
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SSC/0.1% SDS by rotating again at 65°C in the hybridization oven. The membrane was 
layed on a paper towel and when being dry was wrapped in a cling film. A phosphor sto-
rage screen was exposed to the radioactivity on the membrane for at least 24 hours and 
imaged with the PhosphorImager (Storm860). 
 
 
3.15. Analytical-chemical methods 
 
Plasma free fatty acid composition 
 
3.15.1. NEFA c kit (Wako) 
For relative quantification of the free fatty acid – composition of the sera from Atgl-/- mice 
and wild type mice by GC-MS, a NEFA c kit was performed to determine the total 
amount of free fatty acids. This concentration then provided a reference for the quantita-
tive analysis. The Wako enzymatic method uses the acylation of coenzyme A (CoA) by 
fatty acids in the presence of acyl-CoA synthetase (ACS). The produced acyl-CoA is 
then oxidized by acyl-CoA oxidase (ACOD) thereby generating hydrogen peroxide in the 
presence of peroxidase (POD). This enables the oxidative condensation of 3-methy-N-
ethyl-N (β-hydroxyethyl)-aniline (MEFA) with 4-aminoantipyrine and forms a purple co-
lored adduct which can be measured colorimetrically at 562 nm.  
First, blood samples were centrifuged for 10 to 15 min. at 1,500-2,000xg and RT to sepa-
rate the plasma from blood cells. Plasma partitioned in the upper phase, WBC in the 
interphase and RBC in the lower phase. Plasma was pipetted off and transferred to fresh 
reaction tubes. With the provided NEFA c kit standard solution a dilution series was pre-
pared (concentrated - 1:2 – 1:4 – 1:8 – 1:16). 5 µl of every standard dilution and every 
sample were pipetted in duplicates into a 96 wells microplate. As blank measurement 5 
µl ddH2O were used instead. 150 µl of reagent #1 were added to the wells and plate was 
incubated for 10 min. at 37°C. Next, 75 µl of reagent #2 were added and again incubated 
for 10min. at 37°C. The absorbance was measured in a spectral photometer at 562 nm. 
To determine the concentration of NEFA in the plasma samples a standard calibration 
line was created with the known concentrations of the standard dilutions and the accord-
ing measured absorbancies. 
c (standard solution) = 28.2 mg/dl 
conversion factor: 𝑚𝑔/𝑑𝑙 × 0.035 = 𝑚𝑚𝑜𝑙/𝑙 
For further analysis equal quantities of NEFA were used (e.g. 10 µg NEFA = x µl sample) 
and were adjusted to 200 µl with ddH2O. 
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3.15.2. Lipid extraction (acidic Folch) 
For the extraction procedure it is very important to use clean PYREX® glass tubes since 
chloroform is able to degrade some types of plastics. Before using the tubes they were 
cleaned in the dishwasher and rinsed with CHCl3 and ether or methanol to get rid of any 
disturbing substances that could interfere with the mass spectrometric analysis. 
 
3.15.2.1. Lipid extraction of plasma 
Every plasma sample was mixed with 1 ml of the acidic Folch reagent. For quantification, 
45 µl of an internal standard solution (C17:0) were added per ml Folch solution. The 
samples were vortexed vigorously (to get bigger volumes for easier separation one could 
have added another ml of the Folch solution and vortexed again). 350 µl of ddH2O were 
added and tubes were centrifuged for 15 min. at RT and 2,200 rpm (Beckman GS-6R). 
The upper aqueous phase and the proteins (white interphase) were removed. Once 
again the samples were vortexed and centrifuged for about 5 min. at 2,200rpm to re-
move remaining water drops. Finally, the organic phase was evaporated with N2 at about 
40°C. The lipid “pellets” were dissolved in 500 µl CHCl3 : MeOH (2:1) and transferred into 
amber glass vials. Lipids were ready then for measurement with HPLC-MS. For GC-MS, 
free fatty acids had to be silylated.  
 
3.15.2.2. Silylation 
Silylation is the introduction of a silyl group (R3Si–) to a molecule so that functional 
groups which present a problem in gas chromatographic separation can be derivatized 
by silylating reagents. In our specific case, it was the replacement of acidic hydrogens in 
free fatty acids with the alkylsilyl group trimethylsilyl (-SiMe3). N,O-
Bis(trimethylsilyl)trifluoroacetamide (BSTFA) thereby served as trimethylsilyl donor. The-
reby, the derivatives become generally less polar, more volatile and more thermally sta-
ble.  
The samples were again evaporated with N2 for at least 1 hour at about 40°C (samples 
had to be completely dry for further silylation). 50 µl BSTFA and 100 µl pyridine were 
added. Samples were vortexed until everything had completely dissolved and finally 
were transferred into a pointed glass insert/plastic outside vial for GC-MS-
measurements. 
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3.15.2.3. Lipid extraction of tissue 
Generally, lipid extraction from tissues follows the same principle as for plasma. Again, 
clean glass tubes were prepared. First, 1.5 ml MeOH were pipetted into the glass tubes. 
Liver, heart, and brain samples were weighed and added to the methanol. Tissue was 
homogenized with an ultra turrax. Homogenate was mixed with 3 ml CHCl3 and 45 µl 
glacial acetic acid (1%). This mixture was rotated on a rotating wheel (Labinco) at RT for 
2 to 3 hours. 1 ml HSL buffer containing 1% PI was added to every tube. Samples were 
centrifuged for 15 min. at 3,500 rpm (Beckman GS-6) and RT. The lower organic phase 
was soaked up with a Pasteur pipette and transferred into a new glass tube. The upper 
aqueous phase was disposed. The protein pellets of the interphase were dried under the 
fume hood. The organic phase was again evaporated with N2 for about 1 hour at 40°C. 
Lipids were - depending on the approximate amount – dissolved in 100 to 500 µl of a 
CHCl3:MeOH (2:1) mixture and transferred into amber glass vials for HPLC-MS mea-
surements.  
 
3.15.3. Protein determination 
Protein determination of tissue samples was needed as a reference for quantification 
and comparison of lipid species among various samples. First, dried tissue/protein pellet 
was lysed in an appropriate volume of lysis solution composed of 0.3 M NaOH and 0.1% 
SDS. Therefore, samples were shaken in a water bath at 56°C over night.  
Proteins were quantified by using the BCA protein assay kit (Thermo Scientific). In this 
assay, Cu2+ ions are reduced in an alkaline medium by proteins to Cu+ and form blue-
colored chelate complexes with the proteins. BCA in a second step forms a purple co-
lored adduct with the produced Cu+ ions which absorbs light at 562 nm. The BCA rea-
gent (blue) first had to be diluted 1:50 with provided reagent 2 (white). With a protein 
standard (BSA; 2 mg/ml; Thermo Scientific) a dilution series (1 mg/ml – 0.75 mg/ml – 0.5 
mg/ml – 0.25 mg/ml – 0.125 mg/ml – 0.0625 mg/ml - blank) was created. The protein 
standard was diluted with the lysis solution which also served as blank. One sample per 
tissue was used for preparation of three different dilutions (1:10, 1:25, 1:50) to find out 
which one had a protein concentration in the linear range of the straight calibration line. 
10 µl of the standard and sample dilutions were pipetted into a 96 well microplate and 
200 µl of the prepared BCA reagent were added. The plate was incubated at 37°C for 
half an hour. Absorbances were measured in a spectral photometer at 562 nm. A stan-
dard calibration line was created with the standard dilutions and protein concentration of 
tissue samples were determined with the linear equation (y=kx+d). 
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3.15.4. HPLC-MS 
Phospholipids were analysed by tandem mass spectrometry. Samples dissolved in 
CHCl3:MeOH (2:1) were further diluted and 4 µl were injected into the Accela ultra HPLC 
system (Thermo Scientific). The various lipids were separated by their different retention 
times in the HPLC system due to interactions with the C18-tails of the column. C18 col-
umns with a hydrophobic alkyl phase are very retentive and give good separation over a 
broad spectrum. The C18 reversed phase Thermo Hypersil GOLD column, 100x1mm 
(0.9 µm), was operated at 50°C. As solvent A we used water (Millipore) and solvent B 
was acetonitrile/isopropanol (5:2, v/v). Both solvents contained 1% NH4Ac (1 M aqueous 
solution) and 0.1% formic acid. For the gradient we started with 35% solvent B, in-
creased to 70% in the first 4 minutes, reached 100% during the next 16.5 min. and 
stayed at 100% for 9.5 min. After each run, the column was equilibrated at starting condi-
tions. The flow rate through the column was settled at 0.250 ml/min. Molecules were 
ionized by electrospray ionization (ESI) in the positive mode with a voltage of 4000 V. 
Thereby, stable MH+ ions were generated. By the electrospray ionization method all sol-
vents were removed so that the ions could be injected into the high vacuum of the mass 
spectrometer. 
Phospholipid species were detected by a triple quadrupole system (Quantum TSQ) from 
Thermo Scientific. A quadrupole is composed of four rods to which direct and alternating 
voltage can be applied at the same time. The two opposing rods always have the same 
phase and polarity. Through permanent changes of the electric field, ions start to oscil-
late in dependence of their m/z-ratio. The quadrupole is programmed in a way so that 
only ions of a certain m/z-ratio have a stable flight path through the detector. In the first 
quadrupole (Q1), the mass/charge-ratio of all incoming positively charged molecules is 
detected sequentially (full scan). In the collision cell (Q2) ions are fragmented by collision 
with gas molecules. The last quadrupole (Q3) is scanning again the mass/charge ratio.  
For the detection of phosphatidylcholine, a precursor ion scan was done. In this case, Q1 
scanned all m/z ratios and sequentially transferred the ions into Q2 where they were 
fragmented. In Q3 only these fragments with a specific m/z-ratio could pass to the detec-
tor. These specific fragments with a m/z-ratio of 184.1 represent the polar head group of 
phosphatidylcholine. If the detector measured ions, the m/z-ratio of the precursor was 
recorded. Argon was used as collision gas with an energy of 30 V and a collision gas 
pressure of 0.7 mTorr.  
In the case of phosphatidylethanolamine, a neutral loss scan (loss of the uncharged 
head group of PE) was applied. Q1 did again a full scan as before, ions were fragmented 
in Q2 and this time Q3 scanned for the specific loss of the neutral head group of PE. The 
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neutral loss scan was done for a m/z-ratio of 141.0. This means that the mass detector 
was recording ions only in the case of this specific mass difference. Argon collision ener-
gy was 25 V this time with gas pressure remaining unchanged.  
C24:0 (12:0/12:0, Avanti Polar Lipids Inc.) PC and PE were added as internal standards. 
Data were processed with the software Excalibur and peak areas were related to the 
internal standards. 
 
 
FIGURE 3.15.1. Illustration of precursor ion scan and neutral loss scan by tandem MS (source: (103)). 
 
 
3.15.5. GC-MS 
Free fatty acids were measured by GC-MS overnight. 
The GC-MS is composed of two major building blocks: the gas chromatograph and the 
mass spectrometer. A difference in the chemical properties of the various fatty acids se-
parates them as they travel the length of the column. The fatty acids need different 
amounts of time (retention time) to elute from the gas chromatograph and therefore 
reach the mass spectrometer consecutively. This allows the mass spectrometer to cap-
ture and detect the ionized molecules separately. Each fatty acid is broken into ionized 
fragments and detected using its mass to charge ratio in a full scan mode. 
 
~ 42 ~ 
 
 
FIGURE 3.15.2. Schematic representation of the quadrupole MS system (image source: (104)). 
 
A Thermo Trace GC ultra coupled to a Thermo DSQ quadrupole MS (ThermoElectron, 
Waltham, MA; USA) was used. The GC was fitted with a HP–5MS fused-silica capillary 
column (30 m x 0.25 mm (0.25 µm)). Helium was used as a carrier gas at a constant 
flow-rate of 1.5/1.0 ml/min. Initial column temperature was 110°C for 4 min, followed by 
an increase of 20°C/min to 300°C and an isothermal hold of 10 min. The mass spectro-
meter transfer line was kept at 310°C. Positive electron ionization (EI) was performed at 
an electron energy of 70 eV and an emission current of 0.150 A. Identity of analytes was 
verified in full-scan-mode. Data were again processed with Excalibur. 
 
 
3.16. Statistical analysis 
The results were expressed as a mean ± standard error of the mean for each group. 
Comparisons between groups were made by unpaired two-tailed Student’s t-test. p val-
ues of <0.05 were considered statistically significant. 
• p < 0,05  - * 
• 0,05 > p > 0,001 - ** 
• 0,001 > p - *** 
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4. Results 
 
4.1. RNA experiments 
4.1.1. Real-time PCR pretests 
4.1.1.1. Primer test run 
The actual real-time PCR measurements aimed at comparing mRNA levels of the four 
selected DHA-synthesizing enzymes (FADS1, FADS2, ELOVL2, 17β-HSD4) in wild type 
and Atgl-/- mice to determine whether ATGL deficiency had an impact on the expression 
of the enzymes. However, several preliminary tests had to be done in advance to ensure 
correct measurements and relevant results. First, the primer concentration resulting in a 
sufficient amplification of the respective cDNA had to be identified separately for every 
enzyme. Therefore, a preliminary real-time PCR was performed with varying primer con-
centrations and using a WT liver cDNA sample as template. The PCR products were 
loaded on a 1.5% agarose gel to identify the minimal quantity of primers required for suf-
ficient amplification. 
 
FIGURE 4.1.1. Primer concentration test for real-time PCR. Primer test real-time PCR was performed 
using a wild type liver cDNA sample and different volumes of the four primer pairs. One real-time PCR batch 
(20 µl) of each triplicate from the primer test run was loaded on a 1.5% agarose gel that was run at 100 V for 
20 min. Obtained products were in line with estimated amplicon sizes. 100 bp DNA ladder depicted on the 
left was purchased from Invitrogen. Fads1, 110 bp; Fads2, 150 bp; Elovl2, 102 bp; 17β-Hsd4, 112 bp. 
0.5/1.0/1.5 stands for 0.5 µl/1.0 µl/1.5 µl of forward and reverse primer tested. 
 
Based on the amount of product obtained for the different primer concentrations by real-
time PCR (Fig.4.1.1), it was determined that 1 µl of forward and reverse primer was suf-
ficient for good amplification of Fads1 (Δ5-desaturase; 110 bp) and 17β-Hsd4 (perox-
isomal β-oxidation enzyme; 112 bp); 1.5 µl were needed for Elovl2 (elongase; 102 bp). It 
was found that the primers for copying part of the Fads2 gene (Δ6-desaturase; 150 bp) 
bind better to the cDNA than the other primers and/or had more template to copy as they 
resulted in the highest quantity of product. That’s why 0.5 µl of forward and reverse pri-
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mer were applied for further measurements involving Fads2 amplification. As Fads2 pre-
sented the longest amplicon and Elovl2 the shortest, the possibility that the varying sig-
nal intensities also could – at least partly – result from the different amplicon sizes was 
also taken into account. Additionally, the melt curves obtained for the four primer pairs 
were checked for primer dimers or unspecific product peaks. 
 
  
FIGURE 4.1.2. Melt curves of β-Actin. Verification of the absence of primer dimers and/or contamination by 
DNA. The pink lines at the bottom represent blank measurements with either water or RT-minus probe which 
should not result in melt curve peaks. 
 
In case of primer dimers and/or unspecific amplification, a second melt curve peak would 
have been observed at a different melting temperature. Since blank measurements did 
not produce melt curve peaks, the absence of primer dimers and DNA contaminations 
was established (Fig. 4.1.2). All four primer pairs were specifically binding only to the 
genes of interest, not to other sequences or to one another. The small “peak” in the left 
graph (Fig. 4.1.2) could be explained by the configuration of the automatic graphical 
analysis of the real-time PCR machine. According to the manufacturer the analysis re-
sults are valid as long as in the second graph type (right) no further melting temperatures 
are obtained. These verifications by melt curve analysis were repeated for every single 
real-time PCR measurement. 
 
4.1.1.2. Cycle Sequencing 
The remaining two PCR batches from the primer test run were used for a sequencing 
reaction to confirm once more that the primers designed for real-time PCR were specifi-
cally amplifying the genes of interest. Usually purified or plasmid DNA is used for cycle 
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sequencing. Nevertheless, the real-time PCR products were sequenced although they 
still contained residual cDNA template, SYBR Green mastermix and primers which were 
not used up. 
Four sequencing reactions were prepared for every gene, two with the respective for-
ward primers and two with the reverse primers. 
 
Fads1 
Sequences producing significant alignments: 
Transcripts 
Accession Description 
NM_146094.1 Mus musculus fatty acid desaturase 1 (Fads1), mRNA 
QUERY 1 (Score: 84.2; E-value: 1e-14) 
Query 1   CAAATACCTCTNCCTCNTCGGACCCCCNNCNNTCGCNGCCTCNNANACTTCCAGTGGTNC  60 
          ||| ||| ||| |||| ||||||||||  |  | || |||||  | ||||||||||||   
Sbjct 877 CAAGTACTTCTTCCTCATCGGACCCCCAGCCTT-GCTGCCTCT-ATACTTCCAGTGGTAT 934 
 
Query  61   CTTTTCTNTTTTGTGGTTCAGCGGTAAAAA  90 
             |||||| |||||||||||||||| ||||| 
Sbjct  935  ATTTTCTATTTTGTGGTTCAGCGGAAAAAA  964 
 
Fads2 
Sequences producing significant alignments: 
Transcripts 
Accession Description 
NM_019699.1 Mus musculus fatty acid desaturase 2 (Fads2), mRNA 
QUERY1 (Score: 194; E-value: 2e-47) 
Query 1   CCGNGCGCCAGGCTCCGTTNCNNTCCTTCCGTTGGGAGGAGATTCAGANGCACAACCTGC 60 
          ||| ||||||||||||| | |   |||||||||||||||||||||||| ||||||||||| 
Sbjct 109 CCGAGCGCCAGGCTCCGATGCCCACCTTCCGTTGGGAGGAGATTCAGAAGCACAACCTGC 168 
 
Query 61  GCACCGACCGGTGGCTCGTCATCGACCGCAAGGTCTACAACGTTACCAAATGGTCCCAGC 120 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 169 GCACCGACCGGTGGCTCGTCATCGACCGCAAGGTCTACAACGTTACCAAATGGTCCCAGC 228 
 
Query  121  GG  122 
            || 
Sbjct  229  GG  230 
QUERY2 (Score: 201; E-value: 1e-49) 
Query 1   CCGAGCGCCNGGCTCCGTTNCCNNCCTTCCGTTGGGAGGAGATTCAGAAGCACAACCTGC  60 
          ||||||||| ||||||| | ||  |||||||||||||||||||||||||||||||||||| 
Sbjct 109 CCGAGCGCCAGGCTCCGATGCCCACCTTCCGTTGGGAGGAGATTCAGAAGCACAACCTGC 168 
 
Query 61  GCACCGACCGGTGGCTCGTCATCGACCGCAAGGTCTACAACGTTACCAAATGGTCCCAGC 120 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 169 GCACCGACCGGTGGCTCGTCATCGACCGCAAGGTCTACAACGTTACCAAATGGTCCCAGC 228 
 
Query  121  GG  122 
            || 
Sbjct  229  GG  230 
QUERY3 (Score: 145; E-value: 6e-33) 
Query 18  GTTGTGCTTCTGAATCTCCTCCCAACGGAAGGTGGGCATCGGAGCCTGGCGCTCGGTGCT  77 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct 164 GTTGTGCTTCTGAATCTCCTCCCAACGGAAGGTGGGCATCGGAGCCTGGCGCTCGGTGCT 105 
 
Query  78   CCCCTCTCCCTGGGTTACCTCCCTT  102 
            ||||||||||| ||||||||||||| 
Sbjct  104  CCCCTCTCCCT-GGTTACCTCCCTT  81 
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Elovl2 
Sequences producing significant alignments: 
Transcripts 
Accession Description 
NM_019423.1 Mus musculus elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 (Elovl2), mRNA 
QUERY1 (Score: 68; E-value: 9e-10) 
Query 14  GCTTCTTNGGGCTTCCCCTGGAACGGCTTTATCCACATTCTCATGGTACTCCTACTACGG  73 
          ||||||| || |   ||||| ||| ||||||||||||||||||| ||||||||||||| | 
Sbjct 542 GCTTCTTTGGACCCACCCTG-AACAGCTTTATCCACATTCTCAT-GTACTCCTACTAC-G 598 
 
Query  74   GCCTG  78 
            ||||| 
Sbjct  599  GCCTG  603 
QUERY2 (Score: 59; E-value: 5e-07) 
Query 10  AAGGTGTTCNGGGTGNNNTCAAGGAGGTTTNGACCACANGTTTTNCAGGTCCAAACACAC  69 
          ||| ||||| |||||    ||| || | || ||||||| | | | ||| || |||||||| 
Sbjct 569 AAGCTGTTCAGGGTGGGTCCAAAGAAGCTTTGACCACAAGGTATCCAGTTCAAAACACAC 510 
 
Query  70   CACCAGATG  78 
            ||||||||| 
Sbjct  509  CACCAGATG  501 
 
17β-Hsd4 
Sequences producing significant alignments: 
Transcripts 
Accession Description 
NM_008292.2 Mus musculus hydroxysteroid (17-beta) dehydrogenase 4 (Hsd17b4), mRNA 
QUERY1 (Score: 68; E-value: 1e-09) 
Query  41   AAGAAAGGGAAAGGGCGGAAAAAGCAGTGGCCAATTTACGATTCAGTTGAAGCAGGC  97 
            |||||  ||||||| ||||||| ||||||||||||| |||||||||||||||||||| 
Sbjct  210  AAGAA--GGAAAGG-CGGAAAA-GCAGTGGCCAATT-ACGATTCAGTTGAAGCAGGC  261 
QUERY2 (Score: 51.8; E-value:7e-05) 
Query 9   TCTGCCACAACCTTGGTCTGGCAGGCTGGAGGAAGCCTTTACCAATTACCCTTGGAAAGT 68 
          |||||||||||||| |||| ||||    |||| |||||||||||||| ||||||  |||| 
Sbjct 206 TCTGCCACAACCTT-GTCT-GCAG--CAGAGG-AGCCTTTACCAATT-CCCTTG--AAGT 155 
 
Query  69   CCCC  72 
            |||| 
Sbjct  154  CCCC  151 
QUERY3 (Score: 93.3; E-value: 3e-17) 
Query 4   CTGCTTTTCNGCCTTTCCTTNTCNNC-CTGCCANAACCTTGTCTGCAGCTGCAGGAAGCC  62 
          ||||||||| |||||||||| |   | |||||| ||||||||||||||| | ||| |||| 
Sbjct 232 CTGCTTTTCCGCCTTTCCTTCTTATCTCTGCCACAACCTTGTCTGCAGCAG-AGG-AGCC 175 
 
Query  63   TTTACCNATTTCCCTTGAAGTCCCCT  88 
            |||||| | ||||||||||||||||| 
Sbjct  174  TTTACCAA-TTCCCTTGAAGTCCCCT  150 
FIGURE 4.1.3. Results from the cycle sequencing reactions. The sequences obtained from cycle se-
quencing were blasted against the mouse genome by using the nucleotide blast program (NCBI). Query, 
sequence obtained from cycle sequencing; Sbjct, aligned sequence from mouse genome. Score: similarity of 
two sequences over a range (dependant on the search parameters). E-value: probability of the score being 
generated by chance (dependant on the size of the database and the length of the hit). 
 
The least exploitable sequencing reaction occurred for FADS1 where only one useable 
result was obtained with the forward primer. However, by blasting the sequence against 
the mouse genome (mus musculus; taxid: 10090) the one significant alignment that was 
found was for (mRNA) Fads1. In case of FADS2, three of the four reactions provided 
results whereas two of the four contained the forward primer. These two sequences were 
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almost identical. Again, significant alignments were produced only for the expected tran-
script. For ELOVL2, two sequences resulted in significant and correct alignments, one 
starting from the forward and one starting from the reverse primer. Nevertheless, the 
coverage was worse for ELOVL2 than for all other enzymes. For 17β-HSD4, two reac-
tions containing the reverse primers and one reaction containing the forward primer pro-
duced sequences aligning with the expected mRNA. To sum up, all 4 primer pairs ampli-
fied the correct target sequences and were therefore specifically binding to the expected 
transcripts. 
 
4.1.1.3. PCR-efficiency 
For all four target genes and the housekeeping gene the cycle threshold with the ideal 
correlation between different amounts of cDNA used and fluorescence signal emitted 
had to be determined. Furthermore it had to be established which dilutions of cDNA 
samples would result in a Ct value of about 20 to maximum 25 at this cycle threshold. 
This test run was done with a pool including all samples. Of course it would have been 
preferable to test the samples separately but that wasn’t reasonably practicable consi-
dering the time and/or costs involved. With the pooled samples, dilutions were prepared 
at ratios of 1:5 (10 ng(cDNA)/µl), 1:25 (2 ng/µl), 1:125 (0.4 ng/µl) and 1:625 (0.08 ng/µl) 
and Ct-values were determined for all genes by real-time PCR. 
 
 
FIGURE 4.1.4. β-Actin amplification plots of standard dilutions. The higher the dilution ratio of the dupli-
cates of the four standard dilutions the higher the threshold Ct-values. For perfect logarithmic amplification, 
Ct-values should be two cycles apart. The greater difference between the Ct-values in the graph above indi-
cates that the PCR-reaction was not a 100% efficient. Cycle threshold set at 0.5 resulted in the best-fitting 
correlation (R2) and slope (k) of the linear trend line. ΔRn, magnitude of normalized fluorescence. 
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The target genes’ Ct-values were plotted on the y-axis against the logarithm of the re-
spective amount of cDNA on the x-axis (Fig. 4.1.5). The correlation coefficient (R2) that 
resulted from the linear trend line had to be at least 0.997. 
 
 
FIGURE 4.1.5. Real-time PCR standard curve for β-actin. This is the standard curve (linear trend line) 
resulting from the Ct-values at a cycle threshold of 0.5 on the y-axis plotted against the logarithmic quantity 
of cDNA used on the x-axis. The coefficient of determination (R2) of almost 1 indicates a good correlation 
between the four dilutions. The slope of -3.5 shows that the PCR reaction efficiency was below 100%. 
 
 
The PCR efficiency was tested for the housekeeping gene and the four target genes: the 
dilutions V1 and V2 resulted in threshold Ct-values between 20 and 25. For all further 
runs the V2 dilution was used in order to use as little cDNA as possible. 
Concerning the PCR efficiency, some standard curve slopes were more positive than -
3.32. This was most likely due to pipetting problems as it can be assumed that sample 
quality was acceptable since RNA quality was checked on an agarose gel. Most of the 
standard curves were more negative than -3.32. Accordingly, the PCR efficiency was not 
exactly 100% which is not unusual. 
The blank measurements were negative. 
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In the following (4.1.2 – 4.1.5), the terms ‘mRNA levels’ and ‘expression’ stand for relative quanti-
fication (as opposed to absolute quantification). Relative quantification means that real-time PCR 
measurements do not result in absolute mRNA copy numbers. Instead, the values obtained are 
relative to the expression levels of a housekeeping gene (β-Actin) (Materials and Methods, p.30). 
 
4.1.2. Fed mice 
In the first actual real-time PCR measurements the expression of the selected DHA-
synthesizing enzymes (FADS1, FADS2, ELOVL2, 17β-HSD4) in mice deficient for ATGL 
was compared with the expression in wild type mice. 
Liver and heart of Atgl-/- and WT littermates were dissected. RNA was isolated using the 
TRIzol reagent (Invitrogen), the RNA concentration was measured with Nanodrop and its 
quality was checked on a 1% denaturing RNA agarose gel. 
 
 
FIGURE 4.1.6. RNA agarose gel. RNA was isolated from liver and heart of fed mice. 5 µg RNA were loaded 
on a 1% RNA agarose gel and separated at 90 V for 20 min. A2, wild type; A0, Atgl-/-; CM, cardiac mus-
cle/myocytes; rRNA, ribosomal RNA. 
 
RNA quality looked good as all three ribosomal RNA bands (28S rRNA, 18S rRNA, 5S 
rRNA) were detectable (Fig.4.1.6) and no smear was visible. RNA quality is highest if the 
28S rRNA band is approximately twice as intense as the 18S rRNA band. This was the 
case for most of the RNA samples shown in figure 22 above. 
 
~ 50 ~ 
 
 
RNA isolated from liver and heart of fed Atgl-/- and WT mice was reverse transcribed and 
used to determine relative expression levels of selected enzymes involved in the DHA 
biosynthesis pathway. In the liver, expression levels were the same for KO and WT mice 
(Fig.4.1.7). mRNA levels were however downregulated in the heart of KO mice. This 
reduction was significant for all genes except for Elovl2 (although this might be due to 
the high standard deviation) (Fig.4.1.8). FADS1 and FADS2 mRNA levels were reduced 
by 37% and 35%, respectively, ELOVL2 and 17β-HSD4 expression was decreased by 
46% and/or 48%. The results suggested an involvement of ATGL in DHA biosynthesis in 
fed mice only in the cardiac muscle. Since there were no obvious differences in the fed 
liver at transcriptional level and since many hepatic lipogenic pathways are regulated by 
the nutritional status, enzyme expression was investigated in fasted mice. 
 
4.1.3. Fasted mice 
 
FIGURE 4.1.9. RNA isolated from fasted mice. Liver and heart were dissected from o/n (12h) fasted wild 
type and Atgl-/- mice. RNA was isolated and 5 µg were loaded on a 1% denaturing RNA agarose gel. The gel 
was run at 90 V for 20 min. rRNA, ribosomal RNA; A2, wild type; A0, Atgl-/-; CM, cardiac muscle; fast, fasted. 
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On the picture at the right (Fig.4.1.9), the 5S rRNA band was very weak but 28S rRNA 
and 18S rRNA bands are far more relevant for RNA quality. As the 28S rRNA band was 
more intense than the 18S rRNA band the RNA quality was high. 
 
 
 
As expected the results for fasted mice were different. On transcriptional level a more or 
less pronounced downregulation of the enzymes was detected in the liver of knockout 
mice compared to wild type (Fig. 4.1.10). For FADS1 and FADS2 this downregulation 
was not significant, probably due to the high standard deviations. Nevertheless, the ex-
pression of FADS1 was reduced by 36%, of FADS2 by 53%. ELOVL2 mRNA levels were 
significantly decreased by almost 73% and 17β-HSD4 expression was only ⅓ (31%) of 
wild type levels. In the heart we obtained similar results as before except for ELOVL2. 
Reduction of ELOVL2 expression by 76% in knockout mice compared to wild type mice 
not only was significant but also more pronounced this time (Fig. 4.1.11). These observa-
tions supported the notion that ATGL has a putative function in DHA synthesis but is 
differently regulated in liver and heart.  
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FIGURE 4.1.12. Comparison of relative mRNA levels in fed and fasted mice. Relative mRNA levels in 
the liver of fasted mice were compared to those in the liver of fed mice. WT, wild type; KO, knockout. Data 
are means ± S.D. (n=4/3 (fed WT/KO), n=3 (fasted)). Statistical significance was determined by the two-
tailed Student’s t test (*, p<0.05; **, p<0.01; ***, p<0.001). 
 
Next, mRNA levels in fed mice were compared with those in fasted mice to verify 
that/examine if fasting has an influence on and/or induces the expression of target en-
zymes. Comparative analysis of mRNA levels in fed and fasted WT mice revealed that 
expression was higher in fasted mice. This effect was very pronounced for ELOVL2 
(+122%) and especially for 17β-HSD4 (+301%). FADS1 and FADS2 mRNA levels in-
creased only slightly (Fig.4.1.12). Relative expression tended to be downregulated for all 
genes except for 17β-Hsd4 in fasted KO mice compared to WT mice. But this reduction 
was only minimal and not significant. These results imply a regulation of DHA synthesiz-
ing enzymes by the nutritional status. 
Since nuclear receptors, like peroxisome proliferator activated receptor alpha, are regu-
lated by feeding/fasting and since a possible interaction between ATGL and nuclear re-
ceptors is assumed, a next step was to examine whether the expression changes in re-
sponse to induced PPARα activity. Therefore, mice were fed a normal chow diet sup-
plemented with the synthetic PPARα agonist WY14,643 during three weeks. 
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4.1.4. PPAR diet 
 
 
 
 
 
FIGURE 4.1.13. RNA isolated from mice on a PPAR diet. Mice were fed either a standard chow diet or a 
chow diet supplemented with the PPARα agonist WY14,643 during three weeks (PPAR diet). Liver, heart 
and brain were dissected, RNA was isolated and 5 µg RNA were loaded on a 1% RNA agarose gel and 
separated for 20 min. at 90 V. A0, Atgl-/-; chow, chow diet; PPAR, chow diet + PPARα agonist; rRNA, ribo-
somal RNA; CM, cardiac muscle; BR, brain. 
 
 
RNA was not degraded; no smear was visible. But RNA quality was not highest as the 
18S rRNA band looked more intense than the 28S rRNA band (Fig 4.1.13). In spite of 
that we used this RNA for reverse transcription and subsequent real-time PCR mea-
surements since according to various findings slightly degraded RNA can still be used for 
real-time PCR measurements without affecting the results (102). 
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4.1.4.1. Real-time PCR 
 
 
 
In the liver, all enzymes except ELOVL2 were highly significantly upregulated on tran-
scriptional level in Atgl-/- mice after administration of the PPARα agonist (Fig.4.1.14 top). 
FADS1 expression was increased by 92%, FADS2 expression was almost six times 
higher (+465%) and 17β-HSD4 mRNA levels were almost 4 times (+289%) as high com-
pared to KO mice on the standard chow diet. The same effect, although less pro-
nounced, was observed in the heart except for cardiac mRNA levels of ELOVL2 which 
also were upregulated in KO mice fed the PPAR agonist (Fig. 4.1.14 bottom). FADS2 
and ELOVL2 expression was increased by 304% and 238%, respectively, FADS1 and 
17β-HSD4 mRNA levels were elevated more than twofold (FADS1: +134%; 17β-HSD4: 
+124%) upon feeding of the agonist. Accordingly, most (all) of the examined enzymes 
are PPARα target genes in the liver as well as in the heart. 
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Expression of FADS1, FADS2, ELOVL2, and 17β-HSD4 was also examined in the brain 
this time because the brain is the organ with the second highest DHA-synthesis rate 
(69). 
Relative expression of the enzymes did not change at all in the brain of Atgl-/- mice upon 
administration of WY14,643 (Fig. 4.1.15). This could be attributed either to different regu-
lation of the enzymes in the brain or to failed transport of the agonist to the brain. 
 
4.1.4.2. Northern Blot 
For verifying purposes (to confirm the results obtained by real-time PCR), mRNA levels 
of DHA-synthesizing enzymes were examined in the liver and the heart of ATGL defi-
cient mice on a PPAR diet and of ATGL deficient mice on a chow diet by doing a North-
ern blot.  
 
4.1.4.2.1. Preparation of probe I 
The first blots were done with probes synthesized from wild type liver cDNA templates 
using the primers designed for real-time PCR. 
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First, a PCR was run at 60°C which was consistent with the real-time PCR annealing 
temperature. At this temperature specific products were obtained only for Fads2 and 
17β-Hsd4 (Fig. 4.1.16) although real-time PCR reaction resulted in specific products for 
all four genes as shown before (pp.42-46). Therefore a temperature gradient was per-
formed and PCR was repeated with multiple batches at 65°C for the best compromise 
between specificity and high quantity. 
 
FIGURE 4.1.17. Northern blot probes I. PCR was run at an annealing temperature of 65°C with three 
batches for every enzyme/probe. PCR products were loaded on a 1.5% agarose gel, separated for 45 min. 
at 90V, cut out and eluted from the gel. Fads1, 110 bp; Fads2, 150 bp; Elovl2, 102 bp; 17β-Hsd4, 112 bp. 
 
PCR products were separated on an agarose gel (Fig. 4.1.17), cut out from the gel and 
purified by “freeze and squeeze”. The precipitated and dried DNA was resuspended in 
ddH2O and 1 µl of resuspended pellets was again loaded on a gel to determine the con-
centration of the probes and to see if the probes are specific now (only the correct band 
is visible). 
 
  
FIGURE 4.1.18. Purified probes. 1 µl of the resuspended pellets was again checked on a 1.5% agarose gel 
(90V, 30 min.) to determine their concentration. Dilutions were made and loaded on a second gel for better 
estimation. Fads1, 110 bp; Fads2, 150 bp; Elovl2, 102 bp; 17β-Hsd4, 112 bp. 
 
Purified cDNA separated on an agarose gel (Fig.4.1.18) displayed only one band of the 
correct size for all four genes. By comparing the intensities of the four probe bands with 
the ladder intensities the concentration of the resuspended pellets was estimated. 15 ng 
of the probe were then radioactively labeled. 
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4.1.4.2.2. RNA agarose gel I 
Liver and heart RNA samples from Atgl-/- mice fed either a standard chow diet or a chow 
diet supplemented with the PPARα agonist WY14,643 were thawed on ice and 10 µg of 
RNA were separated on a 1% denaturing RNA agarose gel (Fig. 4.1.19).  
 
  
  
FIGURE 4.1.19. RNA isolated from liver and heart of ATGL-knockout mice. RNA samples that were 
already used for real-time PCR measurements were thawed and 10 µg RNA were loaded on a 1% RNA 
agarose gel (90 V, 1.5 h) for Northern blotting. 2 Gels were needed for the 17β-HSD4-blot (liver, heart (upper 
blots)), 2 gels for FADS1 and FADS2. 28S rRNA, 4.7kb; 18S rRNA, 1.9 kb. 
 
RNA should be equally concentrated in all bands which was not the case (Fig. 4.1.19). 
The pictures were taken to see how much RNA was loaded in order to be able to take 
into account the differences in RNA quantity in the analysis. 
 
4.1.4.2.3. Northern Blot I 
The gel was blotted on a nitrocellulose membrane under vacuum o/n. The blot was hy-
bridized with the radioactively labeled probe and a phosphor storage screen was incu-
bated with the blot for 24 h, 72 h, and for 5 days to obtain a better signal with less noise. 
 
 
FADS1 
 
FIGURE 4.1.20. Hepatic FADS1 mRNA levels. RNA was isolated from the liver of Atgl-/- mice being fed/not 
being fed a PPARα agonist. 10 µg of total RNA were transferred to a nylon membrane and hybridized with a 
radioactive probe binding to Fads1. Screen was analyzed after 5 days. w/o, without. 
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Despite the long illumination time, there is still a lot of background noise. However, a 
band was obtained for FADS1 at 3.4 kb (GenBankTM accession number AB072976) 
which was detected only for the samples from KO mice which were fed the PPARα agon-
ist (Fig.4.1.20). Taking into account that RNA intensity on the agarose gel was weaker 
for the PPAR-samples, the conclusion was that FADS1 mRNA levels were upregulated 
upon WY14,643 administration as it was seen by real-time PCR. 
 
FADS2 
 
FIGURE 4.1.21. FADS2 Northern blot. 10 µg of RNA isolated from livers of Atgl-/- mice were blotted on a 
membrane o/n. Radioactive probe was binding to the Fads2 mRNA (1.5 kb). w/o, without. 
 
The radioactive Fads2 probe was not perfectly working (Fig. 4.1.21). While the band at 
1.5 kb (GenBankTM accession number AF126798) was slightly visible, it still looked more 
intense for PPARα agonist-fed mice. However, this signal was too blurred and there was 
too much background noise for a significant result. 
 
17β-HSD4 
 
FIGURE 4.1.22. Northern blot analysis of 17β-HSD4. 10 µg RNA from livers of Atgl-/- mice on a chow diet 
or on a PPARα diet were blotted on a membrane. The blot was hybridized with a radioactive 17β-Hsd4-
probe. mRNA was detected at 2.6 kb (GenBankTM accession number BC022175). w/o, without. 
 
Examining the blot labeled with the probe for 17β-HSD4, a tremendous difference in ex-
pression between KO mice that were fed the PPARα agonist and KO mice fed the stan-
dard chow diet was observed which was in concordance with the results obtained by 
real-time PCR (Fig.4.1.22). Regarding RNA samples isolated from KO mice on a chow 
diet, expression of 17β-HSD4 was completely blunted. Contrary to that, a large quantity 
of radioactive probe bound to RNA isolated from WY14,643-fed mice. 
In conclusion, differences were registered in the expression of all three genes upon ad-
ministration of the PPARα agonist but for FADS1 and especially for FADS2 the results 
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were not convincing. That’s why the preparation of the probe was repeated with specifi-
cally designed primers.  
Concerning the samples from cardiac muscle, no significant signal was obtained for 17β-
HSD4 neither in the “normal” KO mice nor in the PPARα diet-fed mice. Therefore, 
FADS1 and FADS2 expression was no longer examined by Northern blotting. ELOVL2 
expression in the liver was not verified by Northern blotting since no differences in ex-
pression were detected by real-time PCR measurements.  
 
4.1.4.2.4. Preparation of probe II 
Since primers designed for real-time PCR amplified a product of only about 100 bp, spe-
cificity was not as high as it would be for usual Northern blot probes with a length of at 
least 300 to 500 bp. For this reason new primers that amplified a PCR product of about 
800 bp and had an additional EcoRI restriction site were designed. With the restriction 
site the PCR products were cloned into a Bluescript vector (pBluescript II SK+) and puri-
fied at a high copy number. 
First, a PCR was done at an annealing temperature ranging from 65°C to 70°C using a 
wild type liver cDNA template and the newly designed primers. 
 
 
FIGURE 4.1.23. Northern blot probe II. A PCR with a temperature gradient from 65°C to 70°C was done to 
determine the optimal annealing temperature. Products were loaded on a 1% agarose gel (90V, 45 min.). 
Fads1, 810 bp; Fads2, 802 bp. 
 
 
The PCR was repeated at 69°C with 8 more batches for FADS1 and 6 more for FADS2.  
All PCR products were separated on a gel (Fig.4.1.23) and then cut out and eluted from 
the gel. For verifying purposes, 1 µl of the precipitated and resuspended cDNA was 
loaded again on a 1% agarose gel (Fig.4.1.24). 
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The resuspended pellets and 2 µl of the Bluescript vector were digested with EcoRI (the 
vector was additionally treated with calf intestinal phosphatase (CIP) to remove 5’ phos-
phate groups and inhibit its religation). The inserts were purified by a chloroform-phenol-
extraction. The vector was loaded on an agarose gel (Fig.4.1.25), cut out and eluted 
from the gel. 
 
FIGURE 4.1.25. EcoRI digested pBluescript II SK+. The vector was digested with EcoRI for 2h at 37°C 
and loaded on a gel. The 3000 bp fragment representing the digested and linearized vector (pBlue + EcoRI) 
was cut out from the gel. For verifying purposes, the undigested vector (pBlue – EcoRI) was also loaded on 
the gel (1.5%, 90 V, 45 min.). pBluescript II SK+, 3.0 kb; pBlue, pBluescript II SK+; + EcoRI, digested with 
EcoRI; - EcoRI, undigested vector. 
 
On the gel it was detected that the vector already contained some unknown insert 
(Fig.4.1.25; 1000 bp fragment, lane ‘pBlue + EcoRI’). Since the vector (3000 bp) was cut 
out from the gel, this insert was eliminated. The undigested vector migrated differently in 
the gel – not according to its size – due to its circulated plasmid form. Most of the vector 
ran faster because of being supercoiled. The upper band migrating slower represented 
the nicked circle form of pBluescript II SK+. 
Vector and inserts were desalted and 1 µl, respectively, was again visualized on an aga-
rose gel (Fig.4.1.26) to determine their approximate concentration since 3 times more 
insert than vector was used for ligation. 
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Vector and inserts were ligated and transformed into chemically competent E.coli and 
plated onto LB-Amp plates supplemented with X-Gal and IPTG. Plates were incubated at 
37°C o/n and were checked for white colonies the next day. One white colony was de-
tected for the Fads1 probe, two colonies for Fads2. The small number of positive clones 
was probably due to an inefficient digestion with EcoRI caused by disturbing ions since 
insert and vector were not desalted before digestion. These colonies were inoculated 
into 5 ml LB+Amp o/n and a “Mini prep” was done the next day. For verifying purposes, 3 
µl of the purified plasmid DNA were cut with EcoRI and analyzed by DNA electrophoresis 
to see whether these colonies were no false-positive clones (Fig.4.1.27).  
 
FIGURE 4.1.27. Control digest with EcoRI. Aliquots of the DNA purified from positive clones by “Mini-Prep” 
were digested with EcoRI and separated on a 1% agarose gel for 45 min. at 90V to verify integration of the 
insert. 1, Fads1; 2,3, Fads2. Fads1, 810 bp; Fads2, 802 bp. 
 
Since all three colonies were positive, the remainder of the purified DNA was loaded on 
a 1% agarose gel, cut out and eluted from the gel, precipitated with 100% ethanol and 
potassium chloride and dissolved in ddH2O. 1 µl of the resuspended pellets was ex-
amined on another gel (1%) to estimate their concentration and 15 ng DNA were ra-
dioactively labeled. 
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4.1.4.2.5. RNA agarose gel II 
Again, 10 µg RNA of liver samples from Atgl-/- mice with or without PPAR agonist were 
loaded on a denaturing 1% agarose gel (Fig.4.1.28). Two gels were prepared, one for 
FADS1 and the other for FADS2. 
 
  
FIGURE 4.1.28. RNA agarose gel loaded with liver samples. RNA samples isolated from liver of Atgl-/- 
mice fed or not fed the PPAR-agonist WY14,643 were thawed and 10 µg were separated on a denaturing 
1% agarose gel for 1.5 h at constant 90 V. rRNA, ribosomal RNA; A0, Atgl-/-; chow, standard chow diet; 
PPAR, standard chow diet supplemented with WY14,643. 
 
Once more RNA was not equally concentrated (Fig.4.1.28). Since the intensity of bands 
looked different than on the previous gel, it might rather be due to a pipetting error than 
to an imprecise measurement of concentration. 
 
4.1.4.2.6. Northern Blot II 
The gel was vacuum blotted on the nitrocellulose membrane o/n, the membrane was 
incubated with the radioactive probes o/n and the phosphor storage screen was exposed 
to 32P-radioactivity for 72 hours (Fig.4.1.29/Fig.4.1.30). 
 
FADS1 
 
FIGURE 4.1.29. Hepatic FADS1 mRNA levels evaluated by Northern blot. Blotting analysis was per-
formed with 10 µg of total RNA. Nylon membrane was hybridized with 32P-labeled Fads1 probe. w/o, without; 
+, with; WY14,643, PPARα agonist. 
 
This time a more distinct band was obtained for the new FADS1 probe binding to the 
target (Fig.4.1.29). There was still some smear/background visible, maybe resulting from 
partial degradation of the RNA since RNA was thawed already for the 4th time (although 
it didn’t seem to be degraded on the gel). Anyway, an upregulation of mRNA levels was 
clearly visible for FADS1 in PPARα agonist-fed KO mice compared to those on standard 
chow diet and this result confirmed real-time PCR experiments. 
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FADS2 
 
 
FIGURE 4.1.30. FADS2 Northern blots with liver RNA samples. Blot A had previously been hybridized 
with radioactive 17β-Hsd4-probe and was now incubated with the new Fads2 probe. The 17β-Hsd4-
radioactivity on this membrane had decayed over a period of 4 weeks (half-life of 32P: 14 days). Blot B was a 
newly prepared membrane also hybridized with the Fads2 probe. Screen was exposed to radioactivity during 
72 hours. 
 
There was a clear difference in expression for FADS2 this time (Fig.4.1.30). While 
mRNA was only slightly detectable in livers of knockout mice on a standard chow diet, 
the expression was highly induced upon administration of the PPARα agonist WY14,643 
on both blots. 
As seen by real-time PCR measurements, upregulation of expression by WY14,643 was 
much stronger for FADS2 and 17β-HSD4 than for FADS1. 
 
 
4.1.5. Transgenic ATGL 
Since mRNA levels of the selected enzymes were reduced in (fasted) Atgl-/- mice, the 
next attempt was to examine whether expression of FADS1, FADS2, ELOVL2, and 17β-
HSD4 changes when ATGL is overexpressed in wild type as well as knockout mice. If 
ATGL is inducing the transcription of the selected enzymes, mRNA levels should go up 
in response to the overexpressed ATGL protein. Therefore, livers of fasted WT mice 
overexpressing ATGL (99) and hearts of fed WT/KO mice expressing exogenous ATGL 
under a cardiac-muscle specific promoter (α-myosin heavy chain promoter (MHC)) (98) 
were used for following measurements. 
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FIGURE 4.1.31. RNA isolated from mice overexpressing transgenic ATGL. RNA was isolated from liver 
and heart of mice that were expressing only endogenous ATGL or that were overexpressing transgenic 
ATGL specifically in heart and liver. RNA was checked on a 1% RNA agarose gel (90V, 20 min.). A2, Atgl 
wild type; fast, fasted; trans, overexpression of transgenic ATGL; A0, Atgl-/-; CM, cardiac muscle; rRNA, 
ribosomal RNA. 
 
Transgenic mice were created overexpressing exogenous ATGL specifically either in the 
heart or in the liver. RNA was isolated without being degraded but again (at least in case 
of CM) the 18S rRNA band was more intense than the 28S rRNA band which indicates 
that RNA quality wasn’t perfect (Fig.4.1.31). 
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Liver samples were isolated from fasted wild type mice with or without transgenic ATGL 
being expressed exclusively in the liver. The relative expression of the four target en-
zymes was not significantly different between the two phenotypes (Fig.4.1.31). Looking 
at the relative expression levels in the heart of fed mice, again a significant decrease in 
the expression of DHA synthesizing enzymes was observed in Atgl-/- compared to WT 
mice (FADS1: -64%; FADS2: -79%; ELOVL2: -97%; 17β-HSD4: -67%) (Fig.4.1.32). This 
reduction was more pronounced than during the first measurements. It was surprising 
that wild type mice with transgenic ATGL expression in the heart had lower relative 
mRNA levels for all four enzymes than “normal” wild type mice. The more so as this re-
duction was significant - except for 17β-HSD4. Atgl-/- mice overexpressing ATGL exclu-
sively in the heart raised their relative expression levels to those of wild type hearts with 
transgenic ATGL but they didn’t reach “normal” wild type levels. Only for 17β-HSD4, 
mRNA levels were almost as high as in wild type hearts (88%). 
As these results were unexpected, expression of MCAD (medium-chain acyl-CoA dehy-
drogenase) which was already shown to be regulated by ATGL on transcriptional level 
(Haemmerle et al., unpublished data) was checked and could therefore indicate whether 
overexpressed ATGL actually displayed the anticipated activity. 
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In the cardiac muscle a clear influence of ATGL activity on MCAD expression was de-
tected (Fig.4.1.34). Although again mRNA levels were not upregulated in wild type mice 
overexpressing ATGL, no reduction of MCAD expression was registered compared to 
WT mice. Additionally, in KO mice overexpressing ATGL the expression was normalized 
and wild type values were reached. So it was concluded that the observed downregula-
tion of DHA-synthesizing enzymes in wild type mice overexpressing ATGL had to be a 
pathway-specific regulation. 
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4.2. Lipid profiling analyses 
4.2.1. Plasma free fatty acid composition 
In order to determine differences in the composition of free fatty acids between the plas-
ma of wild type and ATGL-knockout mice, free fatty acids were extracted from plasma of 
wild type, Atgl-/- and Hsl-/- mice by an acidic Folch extraction procedure. The concentra-
tion of free fatty acids was determined with the NEFA c kit from WAKO.  
Dilutions of the extracted fatty acids were further subjected to a derivatization with 
BSTFA (trimethylsilyl-donor) and then analyzed by GC-MS. 
 
 
FIGURE 4.2.1. Plasma free fatty acid composition determined by GC-MS. Blood samples were taken 
from wild type, Atgl-/- and HSL-/- mice, plasma was separated and lipids were extracted for FFA composition 
by GC-MS: FFA, free fatty acids; WT, wild type; A0, Atgl-/-; H0, Hsl-/-; C16:0, palmitic acid; C16:1, palmitoleic 
acid; C18:0, stearic acid; C18:1, oleic acid; C18:2, linoleic acid. 
 
No real difference was observed concerning the plasma FFA-composition of wild type, 
Atgl-/- (A0) and Hsl-/- (H0) mice (Fig.4.2.1). Levels of saturated fatty acids C16:0 and 
C18:0 were extraordinarily high. In contrast to the very first FFA measurement by direct 
injection MS/MS (St.Louis; USA), C22:6n-3 or other PUFAs were not detected at all – 
perhaps the concentration was too low for the applied GC/MS measurement. For the 
quantification of these long-chain fatty acids in the plasma, the method still needs to be 
adapted. It was also unclear where the high levels of unsaturated fatty acids came from. 
In any case, the composition of all reagents, buffers and solutions did not explain the 
“contamination” with these saturated fatty acids. 
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4.2.2. Phospholipid analysis 
First let us summarize the lipid profiling results that constituted the starting point of our 
study (p.13/14). The distribution of different lipid species and free fatty acids in cardiac 
muscle was compared between Atgl-/- mice and WT mice. Looking at the TAG profile, 
DHA (C22:6n-3)-containing triglycerides were reduced in mice deficient for ATGL com-
pared to wild type mice whereas mainly triglycerides containing linoleic acid (C18:2) 
were increased (Fig.1.8.2). Very similar results were obtained for phospholipids 
(Fig.1.8.1). A decrease in DHA-containing phosphatidylcholins (PC) and phosphatidyle-
thanolamines (PE) being less pronounced for PS, PI, and CL was observed in ATGL-/- 
compared to WT mice. On the other hand, C18:0/C18:1/C18:2-containing phospholipids 
were elevated in KO mice. In addition the FFA composition revealed reduced levels of 
DHA and increased levels of C18 fatty acids (Fig.1.8.3). 
In order to further understand the correlation between the presence or absence of ATGL 
and changes in the lipid profile, lipids were extracted from liver, heart, and brain of KO 
and WT mice under various conditions. The lipid composition was studied by performing 
a HPLC-MS/MS analysis for phosphatidylcholines and phosphatidylethanolamine. 
 
4.2.2.1. Cardiac Muscle  
 
FIGURE 4.2.2. Mass spectrometer analysis of phosphatidylcholine in mouse hearts. Lipids were ex-
tracted from hearts of wild type and transgenic mice by an acidic Folch and PC composition was measured 
by HPLC-MS/MS. The detailed fatty acid composition of the single PC species is described in table 4.2.1. 
PC, phosphatidylcholine; WT, wild type; chow, fed a chow diet; MHC, myosin heavy chain (heart specific 
promoter for transgenic ATGL); A0, Atgl-/-; PPAR, fed a chow diet supplemented with a PPARα agonist. 
 
 
~ 69 ~ 
 
First, we looked into the fatty acid compositions of the various phospholipid species.  
PC spe-
cies 
Fatty acid composi-
tion I 
Fatty acid composi-
tion II 
Possible C18:3 in-
volvement 
PC 32:0 C16:0/C16:0   
PC 32:1 C16:0/C16:1   
PC 34:1 C16:0/C18:1   
PC 34:2 C16:0/C18:2   
PC 34:3 C16:1/C18:2 C16:0/C18:3 (?)  
PC 36:2 C18:0/C18:2 C18:1/C18:1  
PC 36:3 C18:1/C18:2 C16:0/C20:3 C18:0/C18:3 (?) 
PC 36:4 C18:2/C18:2 C16:0/C20:4 (?) C18:1/C18:3 (?) 
PC 36:5 C16:1/C20:4 C16:0/C20:5 (?) C18:2/C18:3 (?) 
PC 38:4 C18:0/C20:4   
PC 38:5 C18:1/C20:4 C16:0/C22:5  
PC 38:6 C16:0/C22:6 C18:2/C20:4  
PC 40:6 C18:0/C22:6   
PC 40:7 C18:1/C22:6 C18:2/C22:5  
 
TABLE 4.2.1. Fatty acid composition of PC species. For phospholipids of a specific number of C- and H-
atoms there is sometimes more than one possible combination of fatty acids. Column I represents the most 
common composition, column II a lesser common one. Column III lists possible C18:3-incorporation which is 
usually not considered as possibility due to the normally very low concentration of C18:3 in wild type mice. 
 
Fatty acid composition of PC in cardiac muscle was more or less the same for fed wild 
type mice with or without transgenic expression of ATGL (Fig.4.2.2). Nevertheless, in 
contrast to the results for Atgl-/- mice, transgenic mice overexpressing ATGL in the heart 
showed a trend towards an increase of DHA-containing PC and reduced 
C18:0/C18:1/C18:2-containing PC. Atgl-/- mice overexpressing ATGL in the heart pre-
sented a completely restored lipid profile since fatty acid composition was the same as 
for fed wild type mice. The difference between knock-outs and wild types in the lipid pro-
file was balanced out by replacing the knocked-out Atgl. ATGL-deficient mice showed 
again a decrease in DHA-containing PC versus an increase of 
C18:0/C18:1/C18:2(C18:3?)-containing phospholipids. KO mice that were fed the 
PPARα agonist WY14,643 mostly had a similar phenotype to Atgl-/- mice (but with some 
variations) instead of the expected restored lipid profile. 
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FIGURE 4.2.3. Results from HPLC-MS/MS analysis of PE composition in mouse hearts. Fatty acid 
composition of the single PE species can be seen in table 4.2.2.  PE, phosphatidylethanolamine; WT, wild 
type; chow, fed a chow diet; MHC, myosin heavy chain (heart specific promoter for transgenic ATGL); A0, 
Atgl-/-; PPAR, fed a chow diet supplemented with a PPARα agonist. 
 
 
PE spe-
cies 
Fatty acid composi-
tion I 
Fatty acid composi-
tion II 
Possible C18:3 in-
volvement 
PE 34:2 C16:0/C18:2   
PE 34:3 C16:1/C18:2 C16:0/C18:3 (?)  
PE 36:2 C18:0/C18:2 C18:1/C18:1  
PE 36:4 C18:2/C18:2 C16:0/C20:4 (?) C18:1/C18:3 (?) 
PE 36:5 C16:1/C20:4 C16:0/C20:5 (?) C18:2/C18:3 (?) 
PE 38:4 C18:0/C20:4   
PE 38:5 C18:1/C20:4 C16:0/C22:5  
PE 38:6 C16:0/C22:6 C18:2/C20:4  
PE 40:6 C18:0/C22:6   
PE 40:7 C18:1/C22:6 C18:2/C22:5  
TABLE 4.2.2. Fatty acid composition of PE species. In column I and II the more or less common fatty acid 
compositions of the single PE species are indicated whereas the last column suggests possible linolenic acid 
incorporation. 
 
The data obtained for fatty acid composition of phosphatidylethanolamine in mouse 
hearts largely resembled the PC-composition (Fig.4.2.3). Again, lipid profile was 
normalized to WT levels in KO mice overexpressing transgenic ATGL in the heart. Wild 
type mice with CM-specific expression of exogenous ATGL had again a similar lipid 
composition to wild type mice but with a very slight trend towards an increase of DHA-
containing PL and a decrease of oleic acid/linoleic acid/linolenic acid-containing 
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phospholipids. ATGL-deficient mice presented opposite results, i.e. reduced DHA-
containing PE and increased C18-fatty acids containing phospholipids. The lipid profile of 
KO mice fed WY14,643 was also very similar to the profile of “normal” KO mice. All in all, 
differences between genotypes were less pronounced for PE than for PC. 
 
4.2.2.2. Liver 
 
 
FIGURE 4.2.4. Lipid profiling analysis in the liver of wild type and KO mice. HPLC-MS/MS measure-
ments were done to analyze the fatty acid composition of PC in the liver of fasted wild type mice overex-
pressing/not overexpressing transgenic ATGL in the liver and of knockout mice fed/not fed a PPARα agonist. 
Fatty acid composition of PC species in the liver is the same as in the heart (Table 4.2.1). PC, phosphatidyl-
choline; WT, wild type; fast, overnight (12 h) fasted mice; MHC, myosin heavy chain (heart-specific promo-
ter); A0, Atgl-/-; chow, fed a chow diet; PPAR, fed a chow diet supplemented with a PPARα agonist. 
 
It was difficult to compare all four genotypes in the liver since wild type mice were fasted 
and knockout mice were fed. Therefore, the results were displayed in two separate dia-
grams (Fig.4.2.4). In the liver of fasted wild type mice overexpressing transgenic ATGL 
we observed almost the same lipid profile as for wild type mice but we did not observe 
this trend towards an opposite profile of ATGL-deficient mice, meaning an increase in 
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DHA-containing phospholipids and a decrease in C18-FA-containing lipids, that was 
seen in the heart (Fig.4.2.2). Contrary to the heart, the liver of ATGL-deficient mice dis-
played only a slight reduction in DHA-containing PC (especially PC 40:6) and a lesser 
increase in C18-FA-containing PC (PC 36:2) compared to the liver of fasted WT mice  
considering the percentage distribution (provided that lipid profiles of fed and fasted liver 
can be compared anyway). ATGL-deficient mice that were fed the PPARα agonist mostly 
had a very similar lipid profile to KO mice on a standard chow diet with very few but very 
pronounced differences, especially for PC 34:1 (C16:0/C18:1) which was dramatically 
increased and for PC 36:2 (C18:0/C18:2; C18:1/C18:1) that was significantly reduced, 
compared to KO mice.  
 
 
FIGURE 4.2.5. Distribution of PE species in mouse liver analyzed by HPLC-MS/MS. Fatty acid composi-
tion of PE species can be seen in table 4.2.2. PE, phosphatidylethanolamine; WT, wild type; fast, overnight 
(12 h) fasted mice; MHC, myosin heavy chain (heart-specific promoter); A0, Atgl-/-; chow, fed a chow diet; 
PPAR, fed a chow diet supplemented with a PPARα agonist. 
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The PE composition in the liver of the different mice varied along the same lines as the 
PC composition (Fig.4.2.5). Fasted wild type mice, expressing exogenous ATGL or not, 
had a very similar profile. ATGL-deficient mice showed again a slight reduction in DHA-
containing PE and only a slight increase in C18-FA-containing PL regarding the percen-
tage distribution. PPARα agonist-fed KO mice principally had a similar lipid composition 
to ATGL-deficient mice with all differences of the KO mice profile to the profile of WT 
mice being more pronounced except for some phospholipids, especially PE 38:4 
(C18:0/C20:4). But there were also significant differences between PE and PC lipid pro-
file, namely regarding PE 36:4 (C18:2/C18:2; C16:0/C20:4; (C18:1/C18:3)) which was, 
contrary to PC 36:4 (Fig.4.2.4), increased in PPARα agonist-fed KO mice compared to 
ATGL-deficient mice. Looking further at the percentage distribution, PE 36:4 was in-
creased in Atgl-/- mice compared to WT mice which was not the case for PC 36:4 
(Fig.4.2.4). The PE profile thus was more in line with the trend of C18-fatty acids being 
increased in Atgl-/- mice.  
Nevertheless, the only statement that could be made considering the phospholipid profile 
in the liver was that hepatic overexpression of ATGL in wild type mice did not change the 
distribution of PC and PE species and feeding of the PPARα agonist WY14,643 did not 
normalize the lipid profile to WT levels. 
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4.2.2.3. Brain 
 
 
FIGURE 4.2.6. HPLC-MS/MS analysis of fatty acid composition of PE and PC in the brain. Lipids ex-
tracted from the brain of ATGL-deficient mice that were fed a standard chow diet supplemented/not supple-
mented with the PPARα agonist WY14,643 were analyzed for fatty acid composition of PE and PC by HPLC 
coupled to a triple-quadrupole mass spectrometer. Fatty acid composition of PC and PE species is depicted 
in table 4.2.1 and table 4.2.2. A0, Atgl-/-; chow, fed a chow diet; PPAR, fed a chow diet supplemented with a 
PPARα agonist. 
 
The comparison between the lipid profiles in the brains of mice fed a standard chow diet 
or a chow diet supplemented with the PPARα agonist WY14,643 during three weeks 
revealed no significant differences for fatty acid composition of PC and PE species as it 
was the case for relative mRNA levels of target genes. 
In summary, the data of the lipid profiling analysis show that fatty acid composition in KO 
mice can be restored by overexpression of exogenous ATGL but cannot by feeding a 
PPARα agonist.  
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5. Discussion 
The adipose triglyceride lipase, short ATGL, is a very important enzyme of the lipolytic 
pathway. Especially during times of high energy demand, stimulated lipolysis depends 
on this enzyme which fulfills the first of three steps in the breakdown of triglycerides into 
glycerol and free fatty acids inside lipid droplets of WAT (21, 54). These free fatty acids 
are the main energy sources used for mitochondrial ATP production by β-oxidation (1). 
When ATGL is knocked out in mice this causes a severe phenotype: Mice are obese, 
they accumulate triglycerides in almost every organ and finally die from cardiac insuffi-
ciency due to this lipid accumulation (31). A similar phenotype can be observed in hu-
mans suffering from NLSDM caused by autosomal recessive mutations inside the Atgl 
gene (34). 
Since ATGL proved so crucial for the lipid metabolism we were interested in the lipid 
profile of Atgl-/- mice compared to wild type mice. At the very start we made an interest-
ing discovery: In the cardiac muscle of mice deficient for ATGL, phospholipids - especial-
ly phosphatidylcholine (PC) and phosphatidylethanolamine (PE), but also phosphatidyl-
serine (PS), phosphatidylinositol (PI), and cardiolipin (CL) - containing docosahexaenoic 
acid (DHA) were reduced. On the other hand, lipids with incorporated C18 fatty acids 
were increased. The same effect was observed for triglycerides. 
Based on these findings we wanted to identify the link between missing ATGL activity 
and changes in lipid profile, especially in DHA-containing lipids. DHA is an ω-3 polyunsa-
turated fatty acid and can either be taken up by ingestion of fatty cold-water fish like sal-
mon or tuna or gets synthesized from the essential fatty acid α-linolenic acid (C18:3n-3) 
by several elongations and desaturations (67). The first steps in DHA-biosynthesis take 
place in the endoplasmic reticulum where the longer-chain intermediate C24:6n-3 is pro-
duced. This intermediate is further oxidized in the peroxisomes and finally results in do-
cosahexaenoic acid (72). The lion’s share of DHA biosynthesis takes place in the liver, a 
minor part can be produced in the brain and only a minimal amount is synthesized in the 
heart (69). We decided to take a closer look at four of the seven enzymes involved in this 
pathway: FADS2, the Δ6-desaturase, which is the rate-limiting enzyme catalyzing the 
first desaturation, the Δ5-desaturase FADS1, the elongase ELOVL2 and the peroxisomal 
enzyme 17β-HSD4. 
Fed mice 
First, we looked into the regulation of these enzymes on transcriptional level. Liver and 
heart were isolated from fed wild type and ATGL-knockout mice and relative mRNA le-
vels were compared by real-time PCR. As opposed to the heart, where relative mRNA 
levels of all four target genes were reduced in mice deficient for ATGL, the expression of 
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DHA-synthesizing enzymes in the liver was not significantly different between KO and 
WT mice. This would indeed be consistent with the results of the lipid profiling analysis 
where reduced levels of DHA-containing phospholipids were obtained only for the heart 
but not for the liver of fed Atgl-/- mice. However, expression of these enzymes in the heart 
should not have a profound effect on its lipid profile since almost all DHA is synthesized 
in the liver and transported to the heart (69, 70). As no effect of ATGL deficiency was 
detectable on the transcriptional regulation of the DHA-synthesizing pathway in the liver 
and based on the fact that the lack of ATGL activity has severe implications on lipid me-
tabolism which is strongly regulated by the nutritional status and that ATGL activity itself 
is induced by fasting (at least in the liver) (98), expression of the enzymes was examined 
in fasted mice next. 
Fasted mice 
Contrary to the results for fed mice, the comparison of relative mRNA-levels in the liver 
of fasted Atgl-/- mice with those of fasted WT mice revealed interesting insights. ELOVL2 
and 17β-HSD4 expression was significantly decreased in Atgl-/- mice compared to wild 
type mice by 73% and 69%, respectively. FADS2 levels were also reduced by 53% and 
FADS1 levels by 36% in knockouts, although the changes were not statistically signifi-
cant. In the heart all four target genes showed significantly reduced expression in KO 
mice compared to wild type, as before. Thus, the effect of Atgl -/- on DHA biosynthesis in 
the liver could be due to missing regulation/activation of fasting induced signaling path-
ways whereas in the heart this regulation seems to be independent from the nutritional 
status. This concept was also supported by the observations that ELOVL2 and 17β-
HSD4 expression was significantly increased in fasted compared to fed WT mice in the 
liver. FADS2 mRNA levels were also slightly upregulated in fasted WT liver whereas 
FADS1 expression remained almost unchanged. Thus, it was probably not a downregu-
lation of the enzymes in the liver but rather a failed upregulation in response to the fasted 
state of the mice whereas the phenotype in the heart resulted only from the deficient 
ATGL activity and was not correlated to the nutritional status. This interpretation is subs-
tantiated by the findings of Rapoport et al. (69) which show that liver but not heart or 
brain DHA synthesis rates were upregulated by n-3 PUFA-deficient diets. This indicates 
that liver DHA synthesis is regulated by the nutritional status whereas synthesis in the 
heart (or brain) is not. Igarashi et al. (74) reported that diets deficient of C18:3n-3 induce 
the hepatic expression of desaturases and elongases involved in PUFA synthesis. The 
missing upregulation of FADS1 and FADS2 in fasted compared to fed WT mice and/or 
the lesser, insignificant downregulation in fasted compared to fed KO mice can be ex-
plained by the study of Li et al. (105). They describe that fasting did NOT induce desatu-
rase expression in the liver of mice that were killed after 24 hours of fasting (in contrast 
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to the expression of β-oxidation enzymes like 17β-HSD4) since these desaturases are 
dually regulated by PPARα and SREBP-1c. SREBP-1c is responsible for regulating 
genes that are involved in fatty acid synthesis. Hence this transcription factor is important 
to maintain proper levels of intracellular lipids and is inhibited in the fasted state. There-
fore, expression of FADS1 and FADS2 is not totally induced in wild type mice during 
fasting. In fasted ATGL-knockout mice, mRNA levels were further decreased as PPARα 
activity was possibly reduced due to ATGL deficiency. In contrast to that, FADS1 and 
FADS2 expression was equally induced by SREBP-1c in fed WT as well as KO mice 
since ATGL has probably no effect on SREBP1c-activity and/or might not be active in the 
liver in the fed state. But again, it was no full induction due to missing PPARα-activity this 
time. If expression of ELOVL2 and 17β-HSD4 is only stimulated in the fasted state, this 
would further explain why the presence/absence of ATGL had no effect on the relative 
mRNA levels of these genes in fed mice. 
The results lead to the assumption that ATGL activity is needed for fasting induced regu-
latory mechanisms, for instance PPAR activity, and that PPARs then further stimulate 
the DHA/PUFA synthesis. As other PPARα target genes were shown to be downregu-
lated in Atgl-/- mice, a regulatory function of ATGL on the activity of nuclear receptors like 
PPARα has already been suggested (Hämmerle et al., unpublished data). PPARα itself 
is further activated by fasting and regulates gene expression (mainly of genes involved in 
β-oxidation) depending on the nutritional status (106). ATGL could be the underlying 
factor for this fasting-induced activation of PPARα by releasing FFA from TG-stores dur-
ing stimulated lipolysis; these FFA might further act as PPARα ligands. 
PPARα agonist-fed mice 
In order to verify the hypothesis exposed above, the expression of the enzymes in Atgl-/- 
mice was investigated under the influence of enhanced PPARα-activity. For this purpose, 
Atgl-/- mice were fed a chow diet supplemented with the PPARα agonist WY14,643 dur-
ing three weeks. In the liver of the mice fed the PPARα agonist the expression of 
FADS1, FADS2, and 17β-HSD4 was significantly increased by 92%, 465%, and 289%, 
respectively, compared to KO mice fed the standard chow diet. For ELOVL2, no changes 
in expression were detected. Also In the cardiac muscle of KO mice fed the PPARα 
agonist WY14,643 a significant upregulation of the relative expression of FADS1, 
FADS2, and 17β-HSD4 was observed; in contrast to the hepatic mRNA levels, also 
ELOVL2 was upregulated in expression. In the brain, no changes in expression were 
registered upon administration of WY14,643. The expression in the brain could be regu-
lated by other nuclear receptors/transcription factors. But most probably the PPARα 
agonist did not cross the blood-brain-barrier. Hence, FADS1, FADS2, and 17β-HSD4 
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behaved like PPARα target genes in both organs whereas ELOVL2 seemed to be diffe-
rentially regulated in heart and liver.  
Northern blot 
For verifying purposes, the RNA isolated from PPARα agonist-fed KO mice and KO mice 
on a standard chow diet was used to perform a Northern blot and thereby determine ac-
tual expression levels of FADS1, FADS2, and 17β-HSD4. The blots confirmed the results 
obtained by real-time PCR. In the liver, the expression of FADS1 was not strongly in-
duced in WY14,643-fed KO mice. There was still a considerable difference in expression 
compared to chow diet-fed KO mice. For FADS2 and 17β-HSD4 a massive induction of 
expression was detected in PPARα agonist-fed KO mice compared to KO mice on a 
standard chow diet. In these “normally” fed KO mice, labeled mRNA was barely detecta-
ble for FADS2 and 17β-HSD4. These results were in accordance with the respectively 
1.9-fold, 5.7-fold, and 2.9-fold increased expression of FADS1, FADS2, and 17β-HSD4 
obtained by real-time PCR measurements with the only difference that induction of ex-
pression was more pronounced for 17β-HSD4 than for FADS2 on the Northern blot. With 
RNA samples from cardiac myocytes one blot was prepared for labeling with a probe 
specific for 17β-HSD4 but no significant bands were detected although the probe worked 
well for labeling hepatic mRNA samples. Consequently, the expression of 17β-HSD4 in 
the heart had to be extremely low compared to the liver. Thus, Northern blotting con-
firmed that FADS1, FADS2, ELOVL2, and 17β-HSD4 are PPARα target genes, at least 
in the liver. 
Indeed, the bifunctional enzyme (human/rat homologue to the mouse 17β-HSD4) has 
already been shown to be upregulated in the liver when treated with PPARα agonists 
(107). The expression of FADS2, the Δ6-desaturase, also was proven to be regulated by 
fasting in a PPARα dependant manner (108). Its expression was induced approximately 
6-fold when treated with the PPARα agonist WY14,643 (109) which is in absolute con-
cordance with our results. Furthermore, mRNA levels of ELOVL5 (elongase) and FADS1 
were also increased by enhanced PPARα-activity (109) whereas ELOVL2 seems to be 
regulated by fasting in a PPARα-independent way since an influence of PPARα on the 
expression of ELOVL2 could not be detected in previous studies (109). All the more sur-
prising were the results for the cardiac muscle (where expression of ELOVL2 was in-
duced upon feeding of WY14,643) as ELOVL2 expression has been described not to be 
induced by PPARα activity. BUT this applies only to the liver. Since it has been thought 
for a very long time that ELOVL2 was not expressed in the heart at all, what was consi-
dered as the reason for DHA not being synthesized in the heart (69), no references 
about the regulation of cardiac ELOVL2 expression in the heart could be found. It might 
therefore be regulated in a completely different way in the heart. ELOVL2 expression in 
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the liver could depend on PPARβ/δ as this nuclear receptor is sensitive to changes in 
plasma FFA levels and there have also been identified other genes which were upregu-
lated by fasting independently of PPARα (106). Furthermore, DHA itself has a positive 
regulatory effect on the binding of PPARβ/δ to DNA (80) what activates gene expression 
and creates a positive feedback loop. But how important is ELOVL2 activity for DHA bio-
synthesis after all? ELOVL2 specifically elongates C20:5 and C22:5 but these interme-
diates could also be elongated by Elovl5, which has a broad range of substrates (109). 
The missing ELOVL2 activity could consequently be compensated by ELOVL5. Never-
theless, ELOVL2 has the highest and most specific activity against 20:5n-3 (EPA) and 
22:5n-3 in the liver (109) and furthermore, ELOVL5 is also a PPARα target gene and 
therefore most probably downregulated in Atgl-/- mice, itself (109, 110). 
Overexpression of the nuclear transcription factor SREBP1c not only induced the ex-
pression of FADS1 (Δ5-desaturase) and FADS2 but also of ELOVL2 (105, 109). But for 
ELOVL2 the physiological importance of this induction is doubtful since in contrast to the 
desaturases ELOVL2 was not at all regulated by changes in insulin and glucose levels 
(109). Furthermore, it would not be logical if ELOVL2 was the only enzyme of DHA-
biosynthesis induced exclusively by feeding and correlated regulatory mechanisms. 
In conclusion it can be assumed that ATGL plays a role in regulating gene expression of 
several enzymes involved in the biosynthesis of DHA (and/or other PUFAs) in the liver 
as well as in cardiac myocytes. In the liver, this is most likely an indirect effect of ATGL 
which is translated by PPARα (and maybe other nuclear receptors) and has an impact 
only during fasting. 
 
FIGURE 5.1. Schematic representation of the hypothetical regulation of DHA biosynthesis by ATGL 
and the nutritional status in the liver. The nutritional status affects the activity of nuclear receptors 
(PPARα, SREBP1c) which in turn induce the expression of DHA-synthesizing enzymes (FADS1, FADS2, 
ELOVL2, 17β-HSD4). The activation of PPARα by fasting might be mediated by ATGL which itself is acti-
vated by fasting and consequently releases FFA from triglycerides stores. On the one hand FFA act as 
PPARα ligands thereby inducing the expression of desaturases, on the other hand PUFA (DHA, ALA) inhibit 
the expression of desaturases probably via exerting a negative effect on SREBP1c (105).FFA, free fatty 
acids. 
~ 80 ~ 
 
 
ATGL overexpressing transgenic mice 
In order to receive a more precise impression of the role ATGL is playing in DHA biosyn-
thesis, transcription of FADS1, FADS2, ELOVL2, and 17β-HSD4 was examined in WT 
and KO mice that were overexpressing exogenous ATGL. For fasted wild type mice 
overexpressing ATGL in the liver an increase of hepatic expression of target enzymes 
compared to “normal” wild type mice was expected. But, comparing their relative mRNA 
levels, no differences were observed. In the hearts of fed mice with cardiac muscle-
specific overexpression of ATGL, however, even a decrease in expression was regis-
tered for FADS1, FADS2, and ELOVL2 compared to WT mice. This decrease was still 
more pronounced in ATGL-knockout mice (but in this case it was expected). Introduction 
of transgenic Atgl into their knock out genome increased the expression of all four genes 
again but only to the levels of WT mice overexpressing transgenic ATGL. The un-
changed relative mRNA levels in the fasted liver might be due to the fact that the expres-
sion of the enzymes had already been induced as a result of fasting and had reached a 
maximum. Therefore, the overexpression of ATGL had no additional effect. This expla-
nation would be consistent if the only function of ATGL in DHA biosynthesis was to 
transduce fasting induced upregulation of enzyme expression (via PPARs). Exogenous 
ATGL in both, heart and liver, might not have the same activity as endogenous ATGL 
and this exogenous ATGL might have suppressed endogenous ATGL production by be-
ing synthesized in such high quantities. However, protein levels and also TG-hydrolyzing 
activities were shown to be upregulated in transgenic mice (98, 99) what argues against 
a reduced/changed activity of exogenous ATGL, at least considering its TG-hydrolyzing 
function. Therefore, it might rather be a negative feedback mechanism as FADS1 and 
FADS2 have already been shown to be regulated by such inhibitory feedback pathways 
via PPARs (111). Thus, ATGL might activate PPARs and activated PPARs induce 
Δ5/Δ6-desaturase expression which in turn results in increased PUFA-levels. Since in-
creased PUFA on the other hand negatively influence Δ5/Δ6-desaturases (74), overex-
pression of ATGL could in fact result in a negative feedback of the DHA-biosynthesis 
pathway. This would also explain the even lower cardiac expression levels in Atgl-
transgenic mice compared to WT mice and the fact that in KO mice carrying the exogen-
ous Atgl gene expression reaches only the mRNA levels of WT mice with transgenic 
ATGL expression. In any case, the mechanism has to be pathway-specific as MCAD 
expression, in contrast to FADS1, FADS2, and ELOVL2, was not downregulated by 
overexpressed ATGL. 
In summary, the results obtained by real-time PCR measurements lead to the conclusion 
that there is a nuclear receptor-dependant regulation of most enzymes involved in the 
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expression of DHA which is influenced by negative feedback mechanisms. The activity of 
these nuclear receptors further seems to be regulated by ATGL, at least in the liver dur-
ing times of fasting. Most likely, ATGL is necessary in the liver for providing FA as li-
gands for PPARα-activation since exogenous fatty acids are rare/absent during fasting. 
The regulatory effect of ATGL on DHA-synthesizing enzymes in the heart remains elu-
sive; in any case there has to be a fasting-independent transcriptional regulation with 
ATGL-involvement. Nevertheless, DHA-synthesis rates in the heart would probably not 
be sufficient to cause changes in DHA-levels (69). If the effect of ATGL on DHA levels 
consists exclusively in its regulatory function on nuclear receptors (especially PPARα) in 
the liver which in turn regulate expression of some DHA synthesizing enzymes and the-
reby control DHA levels, the lipid profile of PPARα agonist-fed Atgl-/- mice should present 
increased DHA levels. 
Lipid profiling 
Lipid composition of phoshpatidylcholine and phosphatidylethanolamine, the PL species 
with the most important changes concerning DHA-incorporation, was analyzed. For PC 
and PE species in the cardiac muscle of Atgl-/- mice compared to WT mice we confirmed 
the results of previous measurements. In the cardiac muscle we saw again that levels of 
DHA-containing phospholipids were reduced in KO mice compared to wild type versus 
an increase in C18:0/C18:1/C18:2-containing phospholipids. Interestingly, mice trans-
genically overexpressing ATGL in the heart had a similar lipid profile to WT mice BUT 
with a trend towards an opposite lipid profile to KO mice. These results would further 
confirm the hypothesis that reduced cardiac mRNA levels in transgenic mice are the re-
sult of a negative feedback since lipid composition changed slightly into the opposite 
direction of KO mice but not INTO the direction of KO mice. Nevertheless, expression of 
the enzymes in the heart should not significantly influence DHA-levels. Still, it is conceiv-
able that overexpressed ATGL in the heart releases FFA that are transported to the liver 
where they can be used as PPARα ligands and/or precursors for DHA/PUFA synthesis. 
This would further explain why lipid profile was restored in Atgl-/- mice with heart-specific 
overexpression of exogenous ATGL specifically in the heart. Proceeding to the results in 
PPARα agonist-fed mice, the expected normalized lipid profile was not obtained. Con-
trary to that, the lipid profile changed more or less into the same direction as for KO mice 
but this change was still more pronounced. Therefore PPARα-activation could obviously 
not neutralize the effect of ATGL deficiency. In the liver, the lipid profile for WT mice 
overexpressing ATGL was exactly the same as for “normal” WT mice. These results cor-
respond very well to real-time PCR measurements where no changes in the relative ex-
pression of FADS1, FADS2, ELOVL2, and 17β-HSD4 were detected between these two 
phenotypes. Atgl-/- mice showed a similar lipid profile to WT mice in the liver. Neverthe-
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less, contrary to the first measurements (where lipid profile was unchanged in the liver), 
now a slight decrease in DHA-containing PL and an increase in C18-fatty acid containing 
PL were obtained. This might be due to the fact that fasted WT mice were compared to 
fed KO mice and therefore differences in the lipid profile were more pronounced between 
these two genotypes. Thus, the reason for the apparent decrease in DHA-containing PL 
in knockout mice might be due to an increase in DHA-levels in WT mice during fasting. 
Regarding PPARα-activity, the livers from PPARα agonist-fed mice, as it was the case 
for PL in CM, showed a similar lipid profile to KO mice except for some single species. 
So, the activation of nuclear receptors cannot be the only function of ATGL in this path-
way. 
Summarizing the results of lipid profiling in heart and liver, ATGL was shown to operate 
as a regulator of LC-PUFA synthesis since levels of DHA-containing phospholipids were 
reduced in Atgl-/- mice and again increased to wild type levels upon transgenic expres-
sion of ATGL, at least in the cardiac muscle of knockout mice. Although PPARα was 
shown to induce the expression of some DHA-synthesizing enzymes during fasting and 
although this regulation somehow depended on ATGL, the administration of the PPARα 
agonist WY14,643 did not boost the production of DHA in Atgl-/- mice. Therefore, ATGL 
must further be crucial also for some earlier steps in DHA synthesis, most likely for re-
leasing the precursor α-linolenic acid from triglycerides or phospholipids inside biological 
membranes. This would also explain why decreased levels of DHA can also be seen in 
fed mice although enzymes were transcriptionally downregulated only in fasted mice. 
There was no difference in the brain lipid profile between KO mice on a standard chow 
diet and KO mice fed the PPARα agonist for both the composition of PC- as well as PE-
species. This could be attributed to the fact that the agonist not crosses the blood-brain-
barrier. Furthermore, the brain has specific mechanisms to retain DHA for much longer 
than any other organ. In a study, rats fed an α-linolenic acid-deficient diet showed a 3-
fold prolonged half-life of DHA (from 33 to 90 days) in the brain compared to rats fed a 
normal diet due to a downregulated expression of DHA-metabolizing enzymes (69). 
These observations are consistent with the findings of Igarashi et al. (74). Although DHA 
is especially incorporated into brain and retinal phospholipids, no significantly higher le-
vels of DHA-containing PC and PE were obtained in the brain compared to liver and 
heart. ATGL deficiency should have no effect because mice were still able to retain DHA 
in the brain as described above. But DHA is found at very high levels especially inside 
PS and this lipid was not further investigated. 
Conclusion and outlook 
In summary, our study assigns an essential role to ATGL in DHA biosynthesis. At 
present we can conclude from all these results that ATGL has an effect on the expres-
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sion of DHA-synthesizing enzymes and that there has to be an impact of ATGL on nuc-
lear receptors. Whether ATGL just regulates PPAR activity by providing free fatty acids 
as ligands or whether there is another possible interaction remains elusive. The (re-
duced) expression of several selected enzymes of the DHA-biosynthesis pathway in KO 
mice was induced by administration of a PPARα agonist. Consequently FADS1, FADS2, 
and 17β-HSD4 (and maybe ELOVL2 in the heart) were identified as PPARα target genes 
and the regulation by PPARα was shown to depend on ATGL. Still, the induced expres-
sion of DHA-synthesizing enzymes did not increase DHA levels. This could be due to the 
fact that not all enzymes, especially ELOVL2, were restored in their function by adminis-
tration of the PPAR agonist. But if that was the case, EPA (C20:5n-3) (or other interme-
diates) should have accumulated which did not happen. Therefore, any other dysregula-
tion or negative feedback mechanism has to block DHA synthesis at the very beginning. 
It is conceivable that ATGL plays a role in releasing the precursor for DHA biosynthesis 
from biological membranes. C18:3n-3, which is taken up by nutrition and then incorpo-
rated into chylomicrons and lipoproteins, might only be available for DHA synthesis if 
released by the hydrolyzing activity of ATGL. This would be all the more probable if the 
liver also stored some of the dietary α-linolenic acid (C18:3n-3; ALA) and was not imme-
diately using up the available ALA for DHA synthesis because in that case α-linolenic 
acid would need to be released again from its stores. This conclusion is in accordance 
with a paper which describes that with time the labeling of liver lipids shifted from 
C18:3n-3 in TG to C22:6n-3 in PL, what suggests that the liver initially stored at least 
part of the C18:3n-3 as TG and only then converted it to DHA (62). Some very recently 
published results (2010) also match our findings that elevated gene expression does not 
increase DHA levels: this research group reports that n-3 PUFA levels seem to be regu-
lated exclusively by substrate supply and not by alterations in gene expression (112). It 
remains unclear why the effect on the lipid profile only occurs and/or is more pronounced 
in the heart as DHA is almost exclusively synthesized in the liver. DHA-levels might prin-
cipally be low in the liver (since DHA exerts its functions mainly in brain and retina (62, 
63) but also in the cardiovascular system (85, 90)) and DHA might always be very rapidly 
transported to other organs so that the reduced levels have no effect in the liver. Indeed, 
60 minutes after infusion of [U-13C]α-LA, 13C-DHA already appears in the arterial plasma 
(70). Another explanation could be that the liver does no longer distribute any DHA in 
case hepatic production levels are low which causes reduced levels in other organs that 
depend on the liver for DHA supply. The brain that requires DHA the most is less depen-
dent on liver synthesis since it produces higher amounts of DHA itself compared to the 
heart (69) and retains DHA if the liver is no longer providing this FA (62). Furthermore it 
is not yet clear why PPARα agonist-feeding even worsens the phenotype. Induction of 
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PPARα-activity might only increase β-oxidation (111) so that the precursors and also 
DHA are degraded instead of being converted and/or produced. Additionally, if ATGL 
has a PPARα-independent action on DHA-biosynthesis, the logical consequence would 
be that PPARα cannot reverse the Atgl-/- phenotype (but this would also not worsen the 
phenotype).  
A closer look still needs to be taken at C18:3n-3 (ALA) levels, especially in triglycerides 
of serum and liver, to determine if in knockout mice the precursor accumulates instead of 
being converted. If this is not the case, C18:3n-3 has to be consumed in some other way 
since it is implicated in the standard chow diet and consequently taken up by nutrition. 
The accumulation of C18:3n-3-levels already could have been detected in the first lipid-
profiling analyses but these measurements were done by Ingo Streith in St. Louis, US, 
with a method that required the fatty acids of interest to be selected PRIOR to the mea-
surement. The problem was that usually in WT mice C18:3n-3 levels are so low that they 
cannot be measured at all. Therefore, C18:3n-3 was not selected and consequently not 
measured. The difficulty with the following (our) measurements was that only total 
amount of C-atoms and H-atoms was recorded and not the exact FA-composition. 
Usually the major compositions of the various TG-species are known. But for ATGL-
knockout mice it might have been helpful to carry out an additional step and measure the 
exact composition as an accumulation of C18:3n-3 could have been detected in case 
one of the C18-FA in some of the PC/PE-species was C18:3n-3. However, it is more 
likely that C18:3n-3 accumulates in triglycerides in any case (62). The measurement of 
triglycerides hasn’t worked so far though, because the measuring method (HPLC-qTOF) 
is still being established.  
In conclusion, it may be said that further research will be necessary in order to fully com-
prehend the function of ATGL in the DHA/PUFA synthesizing pathway. 
This lipase is not only the main enzyme for hydrolysis of triglyceride stores but also fur-
ther regulates innumerable signaling and gene expression pathways by providing free 
fatty acids and other intermediates of the lipolytic process. 
ATGL is in any case crucial for the smooth functioning of the lipid metabolism and will 
remain an exciting research question still for some time to come.  
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Common abbreviations 
 
AA   arachidonic acid 
ALA   α-linolenic acid 
ATGL   adipose (tissue) triglyceride lipase 
Atgl-/-   homozygous deficiency for ATGL 
ATP   adenosine triphosphate 
BAT   brown adipose tissue 
BCA   bicinchoninic acid 
Bp   base pairs 
BR   brain 
BSA   bovine serum albumin 
BSTFA   N,O-Bis(trimethylsilyl)trifluoroacetamide 
CDS   Chanarian-Dorfman syndrome 
CGI-58   comparative gene identification-58 
CIP   calf intestinal phosphatase 
CL   cardiolipin 
CM   cardiac muscle/myocytes 
Ct   cycle threshold 
DAG   diacylglycerol(s) 
(k)Da   (kilo)Dalton 
(d)dATP  (di)deoxyadenosine triphosphate 
(d)dCTP  (di)deoxycytidine triphosphate 
(d)dGTP  (di)deoxyguanosine triphosphate 
(d)dTTP  (di)deoxythymidine triphosphate 
DEPC   diethylpyrocarbonate 
DG   diglyceride(s) 
DGAT   diacylglycerol/diglyceride acyltransferase 
DHA   docosahexaenoic acid 
(c)DNA   (complementary) desoxyribonucleic acid 
dNTPs   deoxynucleoside triphosphates 
EDTA   ethylenediaminetetraacetic acid 
ELOVL   elongation of very long-chain (fatty acids) 
FADS   Fatty acid desaturase 
fast   fasted 
(F)FA   (free) fatty acid(s) 
G0S2   G0/G1 switch gene 2 
GC   gas chromatography 
HDL   high density lipoprotein 
HPLC   high pressure liquid chromatography 
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HSD   hydroxysteroid dehydrogenase 
HSL   hormone sensitive lipase 
KO   knockout 
LB   lysogeny broth 
MAG   monoacylglycerol 
MCAD   medium-chain specific acyl-CoA dehydrogenase 
MG   monoglyceride 
MGAT   monoacylglycerol/monoglyceride acyltransferase 
MGL   monoacylglycerol/monoglyceride lipase 
MM   mastermix 
MOPS   3-(N-morpholino)propanesulfonic acid 
MS   mass spectrometry 
NEFA   non-esterified fatty acid(s) 
NLSD(M/I)  neutral lipid storage myopathy/ichthyosis 
p   probability 
PC   phosphatidylcholine 
PCR   polymerase chain reaction 
PE   phosphatidylethanolamine 
PI   phosphatidylinositol 
PKA   protein kinase A 
PL   phospholipid(s) 
PP   polypropylene 
PPAR   peroxisome proliferator activated receptor 
PS   phosphatidylserine 
(LC)PUFA  long-chain polyunsaturated fatty acid(s) 
“qRT-PCR”  “quantitative real-time polymerase chain reaction”, correct → 
real-time qRT-PCR real-time quantitative reverse-transcriptase polymerase chain reaction 
(r/m)RNA  (ribosomal/messenger) ribonucleic acid 
RT   room temperature or reverse transcriptase 
SDS   sodium dodecyl sulfate 
SSC   saline-sodium citrate 
TAE   Tris, acetic acid, EDTA 
TAG   triacylgylcerol 
TE   Tris, EDTA 
TG   triglyceride(s) 
TNFα   tumor necrosis factor α 
V   volt 
WAT   white adipose tissue 
WT   wild type 
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